US20020192794A1 - Process for the production of a reversibly inactive acidified plasmin composition - Google Patents
Process for the production of a reversibly inactive acidified plasmin composition Download PDFInfo
- Publication number
- US20020192794A1 US20020192794A1 US10/143,156 US14315602A US2002192794A1 US 20020192794 A1 US20020192794 A1 US 20020192794A1 US 14315602 A US14315602 A US 14315602A US 2002192794 A1 US2002192794 A1 US 2002192794A1
- Authority
- US
- United States
- Prior art keywords
- plasmin
- plasminogen
- solution
- acid
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present invention relates generally to a method of producing plasmin and more particularly to a method of purifying and isolating the plasmin under conditions which stabilize against degradation.
- Fibrin is a white insoluble fibrous protein formed from fibrinogen by the action of thrombin.
- fibrin forms the structural scaffold of a thrombus, which is a clot of blood formed within a blood vessel that remains attached to its place of origin.
- the blood clotting system is maintained in equilibrium and the fibrin deposits are dissolved by the fibrinolytic enzyme system.
- events such as vascular damage, activation/stimulation of platelets, and activation of the coagulation cascade may disturb the equilibrium, which can result in thrombosis or the blockage of a blood vessel by a blood clot.
- Intravascular thrombosis is one of the most frequent pathologici events accounting for greater than 50% of all deaths as well as a variety of other serious clinical problems. Most spontaneously developing vascular obstructions are due to the formation of intravascular blood clots, also known as thrombi. Small fragments of a clot may detach from the body of the clot and travel through the circulatory system to lodge in distant organs and initiate further clot formation. Myocardial infarction, occlusive stroke, deep venous thrombosis (DVT) and peripheral arterial disease are well known consequences of thromboembolic phenomena.
- Plasminogen activators are currently the favored agents employed in thrombolytic therapy, all of which convert plasminogen to plasmin and promote fibrinolysis by disrupting the fibrin matrix (M. A. Creager and V. J. Dzau, Vascular Diseases of the Extremities, ppgs. 1398-1406 in Harrison's Principles of Internal Medicine, 14 th ed., Fauci et al, editors, McGraw-Hill Co., New York, 1998; the contents of which is incorporated herein by reference in its entirety).
- plasminogen activators include a recombinant form of tissue-type plasminogen activator (tPA), urokinase (UK) and streptokinase (SK), as well as a new generation of plasminogen activators selected for improved pharmacokinetics and fibrin-binding properties. All of these plasminogen activators, however, by virtue of their mechanism of action, act indirectly and require an adequate supply of their common substrate, plasminogen, at the site of the thrombus to effect lysis.
- tissue-type plasminogen activator tPA
- UK urokinase
- SK streptokinase
- UK and tPA convert plasminogen to plasmin directly by cleaving the Arg 560 -Val 561 peptide bond.
- the resulting two polypeptide chains of plasmin are held together by two interchain disulfide bridges.
- the light chain of 25 kDa carries the catalytic center and is homologous to trypsin and other serine proteases.
- the heavy chain (60 kDa) consists of five triple-loop kringle structures with highly similar amino acid sequences. Some of these kringles contain so-called lysine-binding sites that are responsible for plasminogen and plasmin interaction with fibrin, alpha 2-antiplasmin or other proteins.
- SK and staphylokinase activate plasminogen indirectly by forming a complex with plasminogen, which subsequently behaves as a plasminogen activator to activate other plasminogen molecules by cleaving the arginyl-valine bond.
- thrombolytic drugs such as tissue plasminogen activator (tPA), streptokinase and urokinase
- tPA tissue plasminogen activator
- streptokinase streptokinase
- urokinase urokinase
- the known plasminogen activators currently used suffer from several limitations that impact their overall usefulness in the elimination of a thrombus. For example, at best, the use of current thrombolytic therapy results in restored vascular blood flow within 90 min in approximately 50% of patients, while acute coronary re-occlusion occurs in roughly 10% of patients. Coronary recanalization requires on average 45 minutes or more, and intracerebral hemorrhage occurs in 0.3% to 0.7% of patients. Residual mortality is at least 50% of the mortality level in the absence of thrombolysis treatment.
- a different approach to avoid the problems associated with the systemic administration of a plasminogen activator to generate sufficient plasmin at the site of the thrombus, is to directly administer the plasmin itself to the patient.
- plasmin compositions may be stabilized at pH 7.0 by including a physiological non-toxic amino acid. This method dilutes stock plasmin solutions stored at low pH with the neutralizing amino acid immediately prior to administration. There are advantages, however, in maintaining low pH of the plasmin composition as long as possible to minimize autodegradation. Ideally, the plasmin will be retained at a low pH until encountering the target fibrin.
- Yago et al. disclose plasmin compositions useful as a diagnostic reagent in U.S. Pat. No. 5,879,923.
- the compositions of Yago et al. comprise plasmin and an additional component which may be 1) an oligopeptide comprising at least two amino acids, or 2) at least two amino acids, or 3) a single amino acid and a polyhydric alcohol.
- the compositions of Yago et al. are formulated at a neutral pH to maintain the enzymatic activity of plasmin.
- Plasmin as a potential thrombolytic agent has numerous technical difficulties. These difficulties include the challenge of preparing pure plasmin that is free of all functional traces of the plasminogem activator used to convert plasmin from its inactive precursor, plasminogen. Preparations of plasmin are typically extensively contaminated by plasminogen activator, streptokinase or urokinase and the thrombolytic activity was, therefore, attributed to the contaminating plasminogen activators rather than to plasmin itself The contaminating plasminogen activators could also trigger systemic bleeding other than at the targeted site of thrombosis. A drawback of streptokinase containing plasmin preparations is that streptokinase can cause adverse immune reactions including fever and anaphylactic shock.
- plasmin as a serine protease with broad specificity, is highly prone to autodegradation and loss of activity. This circumstance provides severe challenges to the production of high-quality plasmin, to the stable formulation of this active protease for prolonged periods of storage prior to use, and to safe and effective administration of plasmin to human patients suffering from occlusive thrombi. Thus, there is need for a method of producing stable plasmin.
- the present invention provides for both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen.
- the produced plasmin is isolated and stored in a low pH buffering capacity agent to provide a substantially stable formulation.
- the purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III by affinity chromatography with an elution at a low pH.
- the reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.
- the method for purifying plasmin comprises cleaving a plasminogen in the presence of a plasminogen activator to yield an active plasmin and removing the plasminogen activator from the active plasmin to form a plasmin solution.
- a low pH-buffering capacity agent can then be added to the final plasmin solution to form a reversibly inactive acidified plasmin.
- the final plasmin solution may be buffered to a pH of between about 2.5 to about 4.
- the plasminogen activator can be removed from the active plasmin by binding the active plasmin to an active plasmin-specific absorbent material to form a bound plasmin.
- an active plasmin-specific absorbent material can comprise benzamidine. Once bound, the active plasmin can be eluted with a low pH solution to form a final plasmin solution. Plasminogen activator may also be further removed by hydrophobic interaction.
- a further method of purifying plasmin comprises cleaving plasminogen to yield an active plasmin and binding the active plasmin to an active plasmin-specific absorbent material to form a bound plasmin.
- the bound plasmin can be eluted with a substantially neutral amino acid to form a final plasmin solution which is substantially free of degraded plasmin.
- the substantially neutral amino acid can comprise an omega-amino acid and is typically filtered out of the final plasmin.
- the final plasmin may also be buffered with a low pH-buffering capacity agent.
- the process for the purification of plasminogen from a plasma source includes the steps of adding the plasminogen containing solution to a plasminogen-specific absorbent material and then eluting the plasminogen from the plasminogen-specific absorbent material at a pH of between about 1 to about 4. The purified plasminogen is then collected as an eluate. Additionally, the process may include methods for the purification of micro- or mini-plasmin(ogen) or other truncated or modified forms of plasmin(ogen).
- FIG. 1 graphically depicts the effect of on plasminogen recovery and lipid removal from CCI filtrate I through PEG precipitation/depth filtration;
- FIG. 2 graphically depicts nephelometry data for CCI extract and the subsequent filtrates I and II;
- FIG. 3 depicts a gel of coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of CCI extract, filtrates and UF/DF retentate;
- FIG. 4 depicts a coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of lysineSEPHAROSE 4B affinity purification of Pmg;
- FIG. 5 graphically depicts a lysineSEPHAROSE 4B chromatogram for the affinity purification of Pmg
- FIG. 6 depicts a coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of pH adjustment of the lysineSEPHAROSE 4B eluate (Pmg) with and without epsilon amino caproic acid present;
- FIG. 7 graphically represents streptokinase activation solution stability following 0.5 M NaCl, 0.25 M ⁇ -ACA stop;
- FIG. 8 graphically represents benzamidine SEPHAROSE 6B chromatogram for the affinity purification of SK activated Pm
- FIG. 9 depicts a coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of benzamidine SEPHAROSE 6B purified Pm;
- FIG. 10 graphically depicts the hydrophobic interaction chromatography (OctylSEPHAROSE 4 FF) chromatogram for the removal of streptokinase
- FIG. 11 depicts a non-reduced SDS PAGE and anti-SK Western Blot.
- the present invention comprises both a method for producing a reversibly inactive acidified plasmin in combination with a low pH-buffering capacity agent and a method for the purification of plasminogen from a plasma source.
- the inactive acidified plasmin solution may also include a stabiliser in addition to being inactivated in buffered solution.
- the process for purifying plasminogen provides for both inactivation and removal of pathogens and the elution of the plasminogen at a low pH.
- the inactive acidified plasmin preparation can be used in the administration of a thrombolytic therapy.
- the present invention includes both a process for the purification of plasminogen and plasmin and concurrently, methods for the inactivation and removal of viral and Transmissible Spongiform Encephalopathies (TSE) contaminants during these processes.
- the starting material, plasminogen can be purified from Cohn Fraction II+III paste by affinity chromatography on Lys-SEPHAROSE as described by Deutsch & Mertz (1970).
- SEPHAROSE is a trade name of Pharmacia, Inc. of New Jersey for a high molecular weight substance for the separation by gel filtration of macromolecules.
- the process may be performed on any plasma source, recombinant source, cell culture source or transgenic source.
- plasma from a waste fraction derived from the purification of immunoglobulin from a chromatographic process can be used as described in commonly owned U.S. patent application Ser. No. 09/448,771, filed Nov. 24, 1999, which is incorporated by reference herein.
- Plasminogen was extracted from this waste fraction (referred to herein as the “caprylate cake I” (CCI)) over a wide range of pH.
- Conditions of extraction can be varied from a pH of about 3.5 to about 10.5 using a variety of buffers capable of providing a pH in this range, including citrate, acetate, tris, imidazole, histadine, HEPES and/or phosphate buffers.
- the extraction can occur at temperatures from about 4° C. to 37° C. and can be run for 1 to 24 hours without deleterious effect.
- the ionic strength can be varied by the addition of about 0.2 Molar sodium chloride without deleterious effect on the extraction of plasminogen.
- lipid and protein impurities and TSE were reduced by precipitation with the addition polyethylene glycol (PEG), in a range of about 1 to about 10% weight/volume or the addition of about 80 to about 120 g/L ammonium sulfate.
- PEG polyethylene glycol
- ammonium sulfate precipitate was removed by depth filtration and the resulting solution placed on a lysine affinity resin column.
- the solubility of plasminogen may be enhanced by the addition of omega-amino acids (lysine, arginine, tranexamic acid, or epsilon amino caproic acid, or combinations or analogues thereof) after extraction of the caprylate cake I.
- Solubility enhancement may be accomplished with from about 0.02 M to about 1 M omega-amino acid, preferably about 0.1 M lysine appears to be sufficient.
- the lysine is preferably removed after the PEG or ammonium sulfate precipitation and depth filtration by diafiltration and the resulting solution placed on a lysine affinity resin column.
- the phrase “lysine affinity resin” is used generally for affinity resins containing lysine or its derivatives or epsilon caproic acids as the ligand.
- the column can be eluted with a low pH solution of approximately 1 to 4.
- the protein obtained after elution from the affinity column is generally at least 80% plasminogen.
- the purified plasminogen is then stored at low pH in the presence of simple buffers such as glycine and lysine or omega-amino acids. Storage at low pH also provides an opportunity for viral inactivation and removal and TSE removal as determined by spiking methods.
- Our studies suggest that plasmin meets the most stringent requirements for 6 log clearance of non-enveloped viruses including one 4 log removal step, and 10 log clearance for enveloped viruses including two independent 4 log elimination steps. In addition to sufficient virus clearance, plasmin has greater than 6 logs of TSE infectivity removal for added safety.
- the plasminogen in solution was then activated to plasmin by the addition of a plasminogen activator, which may be accomplished in a number of ways including but not limited to streptokinase, urokinase, or the use of urokinase immobilized on resin and use of streptokinase immobilized on resin.
- the preferred plasminogen activator is soluble streptokinase.
- stabilizers such as glycerol, and omega-amino acids such as lysine, poly lysine, arginine, epsilon amino caproic acid and tranexamic acid were shown to enhance the yield of plasmin.
- Plasmin was purified from unactivated plasminogen by affinity chromatography on resin with benzamidine as the ligand and elution with a neutral omega-amino acid solution or low pH solution. This step can remove essentially all degraded plasmin as well as the majority of the streptokinase.
- the plasmin is formulated as a sterile protein solution by ultrafiltration and diafiltration and 0.22 ⁇ m filtration.
- the present method additionally includes the steps of activating plasminogen to plasmin using a plasminogen activator and then capturing the formed active plasmin on an active plasmin specific absorbent material.
- the bound plasmin is then eluted with a low pH buffer.
- the eluted plasmin is buffered with a low ph-buffering capacity agent such as an acid.
- the eluted plasmin is buffered to a pH of between about 2.5 to about 4.
- the low buffering capacity of the acidic buffer aids in enabling the reversibly inactivated acidified plasmin to be brought up to physiological pH quickly and then activated when administered as a thrombolytic agent.
- the buffer is added in a concentration at which the pH of the acidified plasmin is raised to neutral pH by adding no more than about 5 times the volume of serum to the acidified plasmin.
- Plasminogen can be cleaved to plasmin by using a catalytic concentration of an immobilized or soluble plasminogen activator.
- Plasmin the principle fibrinolytic enzyme in mammals, is a serine protease with trypsin-like specificity that is derived from the inactive zymogen precursor plasminogen circulating in plasma.
- Plasminogen itself is a 790 amino acid polypeptide having an N-terminus glutamate residue.
- Plasminogen activators such as soluble streptokinase, tissue plasminogen activator (tPA) or urokinase will cleave the single-chain plasminogen molecule to produce active plasmin at the Arg560-Val561 peptide bond.
- the resulting two polypeptide chains of plasmin are held together by two interchain disulfide bridges.
- the light chain of 25 kDa carries the catalytic center and is homologous to trypsin and other serine proteases.
- the heavy chain (60 kDa) consists of five triple-loop kringle structures with highly similar amino acid sequences. Some of these kringles contain so-called lysine-binding sites that are responsible for plasminogen and plasmin interaction with fibrin, alpha2-antiplasmin or other proteins.
- the activation of plasminogen can occur at about 4° C. to about 37° C. and typically takes between about 2 to 24 hours.
- the plasminogen can be cleaved in the presence of stabilisers such as omega-amino acids and glycerol.
- the omega-amino acids can include lysine, epsilon amino caproic acid, tranexamic acid, poly lysine, arginine and combinations or analogues thereof.
- the plasmin solution can be filtered and further stabilised for several days at neutral pH by the addition of omega-amino acids and sodium chloride and applied to benzamidine-SEPHAROSE.
- the active plasmin formed from the cleaving of the plasminogen can then be bound to an active plasmin specific absorbent to substantially remove the plasminogen activator.
- an active plasmin specific absorbent that allows for the capture of the active plasmin.
- Other active plasmin specific absorbents having similar properties as benzamidine may also be used.
- the benzamidine can be immobilized in a solid support medium.
- the solid support medium can be a resin or SEPHAROSE. Additionally, hydrophobic interaction may be used to further remove the plasminogen activator.
- the cleaved plasminogen is typically contained in a solution of amino acids, sodium chloride and glycerol, which allows for stability of the solution for several days at neutral pH before it is applied to a benzamidin-SEPHAROSE column equilibrated with about 0.05 M Tris, pH 8.5, 0.5 M NaCl.
- the column is typically run at 4° C.
- the front portion of the non-bound peak contains high-molecular weight impurities, with the rest of the nonbound peak being represented by residual non-activated plasminogen and by inactive autodegradation products of plasmin.
- the bound plasmin can then be eluted with an acid buffer or with a substantially neutral omega-amino acid.
- the plasmin bound to benzamidine-SEPHAROSE can be eluted with an acidic buffer such as glycine buffer.
- an acidic buffer such as glycine buffer.
- a substantially neutral pH omega-amino acid is used to elute the bound plasmin the final eluted plasmin solution can be substantially free of degraded plasmin.
- the substantially neutral pH amino acid has a pH of value of between about 65 to about 8.5.
- neutral omega-amino acids include lysine, epsilon amino caproic acid, tranexamic acid, poly lysine, arginine, and analogues and combinations thereof.
- the eluted plasmin can be buffered with a low pH-buffering capacity agent.
- the low pH-buffering capacity agent typically comprises a buffer of either an amino acid, a derivative of at least one amino acid, an oligopeptide which includes at least one amino acid, or a combination of the above. Additionally the low pH-buffering capacity agent can comprise a buffer selected from acetic acid, citric acid, hydrochloric acid, carboxcylic acid, lactic acid, malic acid, tartaric acid, benzoic acid, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, alanine, aspartic acid, derivatives or combinations thereof.
- the buffer can be present in the reversibly inactive acidified plasmin at a concentration at which the pH of the acidified plasmin is raised to neutral pH by adding no more than about 4 to 5 times the volume of serum to the composition.
- the concentration of plasmin in the buffered solution can range from about 0.01 mg/ml to about 50 mg/ml of the total solution.
- the concentration of thebuffer can range from about 1 nM to about 50 mM. Of course these ranges may be broadened or narrowed depending upon the buffer chosen, or upon the addition of other ingredients such as additives or stabilizing agent&
- the amount of buffer added is typically that which will bring the reversibly inactive acidified plasmin solution to have a pH between about 2.5 to about 4.
- the reversibly inactive acidified plasmin solution may be further stabilized by the addition of a stabilizing agent such as a polyhydric alcohol, pharmaceutically acceptable carbohydrates, salts, glucosamine, thiamine, niacinamide, or combinations thereof.
- a stabilizing agent such as a polyhydric alcohol, pharmaceutically acceptable carbohydrates, salts, glucosamine, thiamine, niacinamide, or combinations thereof.
- the stabilizing salts can be selected from the group consisting of sodium chloride, potassium chloride, magnesium chloride, calcium chloride and combinations thereof.
- Sugars or sugar alcohols may also be added, such as glucose, maltose, mannitol, sorbitol, sucrose, lactose, trehalose, and combinations thereof.
- Concentrations of carbohydrate added to stabilize the reversibly inactive acidified plasmin solution include a range from about 0.2% w/v to about 20% w/v. Ranges for a salt, glucosamine, thiamine, niacinamide and their combinations can range from about 0.01 M to about 1 M.
- the plasmin being formulated in a buffered acidified water has been found to be extremely stable. It can be kept in this form for months without any loss of activity or the appearance of degradation products of a proteolytic or acidic nature. At 4° C., plasmin is stable for at least nine months. Even at room temperature, plasmin is stable for at least two months. Long-term stability at room temperature is important because it would make this formulation compatible with long regimens of thrombolytic administration. For example, 36 hours administration of thrombolytics such as tissue plasminogen activator or urokinase is common in treatment of peripheral arterial occlusions.
- a feature of the active plasmin as used in the present invention is the maintenance of the plasmin in an acidic buffer and its formulation in acidified water, providing a pure and stable active plasmin. Its efficacy was demonstrated in in vitro assays and in an in vivo rabbit jugular vein thrombolysis model unified, substantially purified or partially purified enzyme such as, but not limited to, plasmin or any composition containing plasmin that is within the scope of the present invention.
- a description of a method of treating thrombolysis and related ailments employing aspects of the claimed invention is disclosed in the application entitled “Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin”, attorney docket number B185 1020 and commonly assigned and filed contemporaneously with the instant application, and which is incorporated herein by reference in its entirety. Additionally, compositions made in accordance with the claimed invention are disclosed in the application entitled “Reversibly Inactivated Acidified Plasmin”, attorney docket number B185 1030 and commonly assigned and filed contemporaneously with the instant application, and which is incorporated herein by reference in its entirety.
- Caprylate cake I is a fraction resulting from a pH 5 caprylate precipitation of resuspended Fraction II+III in the IGIV-C process.
- Plasminogen (Pmg) is extracted from the CCI by solubilizing at a cake:buffer ratio of about 1:10 for 2 to 3 hours at 4° C. with mixing. While several extraction solutions were investigated, the current method was performed with 100 mM Tris pH 10.5 to maintain the pH at or above neutral; a condition favorable to Pmg solubilization from the CCI. Table 1 depicts the extraction solutions investigated along with their final extract pH and Pmg potency. TABLE 1 CCI Extraction Solutions and Their Resulting Final Extract pHs and Pmg Activities.
- lysine derivatives 100 mM L-lysine, 50 mM epsilon amino caproic acid (EACA)
- EACA epsilon amino caproic acid
- Reduction of lipid is achieved through precipitation by the addition of PEG 3350 to 3% -4% w/w.
- PEG 3350 the addition of PEG 3350 to 3% -4% w/w.
- L-lysine the addition of L-lysine to 100 mM prior to PEG addition is necessary to maintain high Pmg recovery in the PEG filtrate, or about 90%.
- lysine only about 25% of the Pmg is recovered in the PEG filtrate (FIG. 1).
- the PEG precipitation proceeds for 1 to 2 hours at 20° C. with mixing.
- Filter aid is added to 4% w/w and mixed prior to depth filtration through a CUNO 30SP followed by further clarification with 0.5 micron and 0.22 micron filters.
- FIG. 1 shows the lipid content, determined by cholesterol and triglycerides concentration, is reduced by 60-70% following PEG precipitation and filtration (CCI Filtrate I).
- CCI Filtrate I is diluted 1:1 with phosphate buffered saline pH 7.5 and held at 20° C. for 1 to 2 hours as precipitation often continues following filtration.
- the CCI Filtrate I is filtered through 0.5 ⁇ m and 0.22 ⁇ m filters to remove any additional precipitate; CCI Filtrate II.
- Nephelometry data for CCI Extract and CCI Filtrates I and II are illustrated in FIG. 2. Note that fibrinogen and apolipoprotein A-1 concentrations are reduced following PEG precipitation.
- the CCI Filtrate II is diafiltered by tangential flow filtration (TFF) against phosphate buffered saline pH 7.5 to reduce the L-lysine concentration such that it will not act as a competitive inhibitor for Pmg binding to the lysine affinity resin.
- TPF tangential flow filtration
- Loading the CCI Filtrate II directly onto a lysine affinity resin without reduction in soluble lysine concentration results in the capture and release of about 4% of the Pmg activity.
- Diluting the CCI Filtrate II 1:1 with TBS (10 mM Tris, 150 mM NaCl pH 7.5) still resulted in capture and release of only about 5% of the Pmg activity.
- TBS 10 mM Tris, 150 mM NaCl pH 7.5
- FIG. 3 shows reduced SDS PAGE for each of the process intermediates discussed thus far.
- the data in FIGS. 2 and 3 illustrate the complexity and heterogeneity of the CCI Extract and subsequent Filtrates.
- lysine affinity chromatography The purpose of lysine affinity chromatography is to purify Pmg, which represents from about 3 to 5% of the total protein in the diafiltered CCI Filtrate II.
- the DF CCI Filtrate II was applied to a Lysine-SEPHAROSE 4B (Amersham Pharmacia #17-0690-01) column equilibrated with 0.01 M NaH 2 PO 4 , 0.15 M NaCl pH 7.5, at 3.5-4.0 A 280 /mL resin. Unbound proteins were washed through the column with the equilibration buffer and the resin was then washed with 0.01 M NaH 2 PO 4 , 0.5 M NaCl pH 7.5 to remove nonspecifically bound protein; no protein was removed.
- Bound protein, Pmg was eluted with 0.1 M Glycine, 0.03 M Lysine pH 3.0 and collected with mixing to maintain low pH.
- FIGS. 4 and 5 show SDS PAGE analysis and the chromatogram of the lysine affinity purification of Pmg, respectively.
- the resin was cleaned sequentially with 0.1 N NaOH and 2.0 M NaCl, 0.1% Triton X-100 and stored in 20% ethanol.
- Table 3 shows Pmg step yield by nephelometry and purity by reduced SDS PAGE. TABLE 3 Lysine Affinity Chromatography Pmg Step Yield and Purity Process Intermediate Step Yield % Pmg Purity % Lysine-SEPHAROSE 4B 75.7 85.9 Eluate
- the determining factors for the optimal conditions for removal of different pathogens by nanofiltration deal mainly with the attainment of a minimum of 4 log infectivity removal of known pathogens, percent product recovery, percent potency remaining, product concentration and product pH. We detected, that PPV and BVDV clearance was >4 log 10 TCID 50 .
- the nanofiltration step has also the capability of removing greater than 4 log of TSE. All product recoveries obtained in the study were ⁇ 95% with no substantial change in Pmg activity.
- caprylate inactivation is very much pH dependent and more efficacious under acidic pH conditions, it was logical to study virus inactivation by caprylate at the low pH lysine affinity chromatography elution step.
- BVDV as a model enveloped virus to study caprylate virucidal activity in lysine affinity eluate.
- the Pmg solution is diluted 1:1 with 20% glycerol, 4° C., to achieve a final condition of 1 mg Pmg/mL 0.05 M glycine, 0.015 M L-lysine, 0.01 M EACA, 10% glycerol pH 7.5. These conditions have been optimized for minimizing Pm autodegradation.
- SK is added to this solution at a 100:1 Pmg:SK molar ratio. The SK reaction mixture is mixed at 4° C. for 16 hours to allow activation of Pmg to Pm.
- benzamidine affinity purification is the separation of unactivated Pmg and impurities, including Pm degradation products, from active Pm.
- the stable SK activation solution pH adjusted to 8.5 in 0.05 M glycine, 0.015 M L-lysine, 0.25 M EACA, 0.5 M NaCl, 10% glycerol, is applied to a Benzamidine SEPHAROSE 6B (Amersham Pharmacia #17-0568-01) column equilibrated with 50 mM Tris, 500 mM NaCl, pH 8.5.
- the Pm, both clipped and intact, is captured by the affinity resin while the aforementioned impurities flow through the column.
- the column is washed with the equilibration buffer until the absorbance at 280 nm reaches baseline.
- the bound Pm is then eluted in either one of two ways: 1) removing the resin and eluting in batch format with 0.1 M Glycine, 0.03 M Lysine pH 3.4; 2) eluting in a column format with 1 M EACA pH 7.5. Elution with EACA pH 7.5 removes only the intact Pm while damaged Pm remains bound to the resin. A step to strip all remaining protein.
- FIG. 8 shows a typical column format, EACA elution profile. The batch elution profile consists only of the unbound protein peak as the resin is then removed from the column for Pm elution.
- the Pm captured and eluted from the affinity resin is 87-91% intact (non-autodegraded) as illustrated in FIG. 9 and ⁇ 99% total Pm.
- the elution of Pm from the benzamidine resin with EACA was unexpected as lysine derivatives such as EACA interact with the heavy chain of Pm while benzamidine interacts with the light chain.
- the purpose of these steps is to remove the Pmg activator SK such that the only remaining fibrin clot dissolution activity is that of Pm.
- the benzamidine affinity step removes >99% of the SK from the Pm as is illustrated in Table 6. TABLE 6 SK removal, as determined by ELISA, by benzamidine affinity chromatography and hydrophobic interaction chromatography. Plasmin Process Step Streptokinase (ng/mL) SK activation 1930.1 Benzamidine-SEPHAROSE unbound 1549.5 Benzamidine-SEPHAROSE eluted Pm 1.9 HIC Unbound Pm 0.7 HIC NaOH strip (SK) 1.3 Final Formulation Pm ⁇ 0.5
- the hydrophobic interaction step using Octyl SEPHAROSE 4 FF acts as a polishing step to remove essentially any remaining SK.
- the final sterile Pm product has no detectable SK by ELISA.
- the 1 M EACA eluate pH 7.5, from the benzamidine affinity column, is adjusted to pH 3.4 and (NH 4 ) 2 SO 4 is added to a final concentration of 0.1 M. This acts as the protein load for the Octyl-SEPHAROSE 4 FF column.
- the column is equilibrated with 0.1 M (NH 4 ) 2 SO 4, 0.1 M Glycine, 30 mM Lysine pH 3.4.
- FIG. 9 is an Octyl-SEPHAROSE 4 FF chromatogram from a proof of principle experiment. Pmg and SK were mixed at a 2:1 Pmg:SK molar ratio and subjected to Octyl-SEPHAROSE 4 FF chromatography. The high levels of SK were used so it could be tracked throughout the chromatographic cycle using an anti-SK western blot.
- FIG. 10 illustrates the removal of SK from the Pm by SDS PAGE and anti-SK western blot.
- the SK standard migrates true to its molecular weight of 47 kDa. Once mixed with Pmg, the SK is modified and migrates faster and as several species. There is no detectable SK in the unbound protein fraction, which contains the bulk of the Pm, by anti-SK western blot (panel B; lane 3).
Abstract
Description
- This is a continuation of International Application PCT/US00/42143 filed Nov. 13, 2000 and published in English on May 25, 2001, itself a continuation-in-part of U.S. application Ser. No. 09/435,331, filed Nov. 13, 1999.
- The present invention relates generally to a method of producing plasmin and more particularly to a method of purifying and isolating the plasmin under conditions which stabilize against degradation.
- Fibrin is a white insoluble fibrous protein formed from fibrinogen by the action of thrombin. In the clotting of blood, fibrin forms the structural scaffold of a thrombus, which is a clot of blood formed within a blood vessel that remains attached to its place of origin. Under normal conditions the blood clotting system is maintained in equilibrium and the fibrin deposits are dissolved by the fibrinolytic enzyme system. Unfortunately, events such as vascular damage, activation/stimulation of platelets, and activation of the coagulation cascade may disturb the equilibrium, which can result in thrombosis or the blockage of a blood vessel by a blood clot.
- Intravascular thrombosis is one of the most frequent pathologici events accounting for greater than 50% of all deaths as well as a variety of other serious clinical problems. Most spontaneously developing vascular obstructions are due to the formation of intravascular blood clots, also known as thrombi. Small fragments of a clot may detach from the body of the clot and travel through the circulatory system to lodge in distant organs and initiate further clot formation. Myocardial infarction, occlusive stroke, deep venous thrombosis (DVT) and peripheral arterial disease are well known consequences of thromboembolic phenomena.
- Plasminogen activators are currently the favored agents employed in thrombolytic therapy, all of which convert plasminogen to plasmin and promote fibrinolysis by disrupting the fibrin matrix (M. A. Creager and V. J. Dzau, Vascular Diseases of the Extremities, ppgs. 1398-1406 in Harrison's Principles of Internal Medicine, 14th ed., Fauci et al, editors, McGraw-Hill Co., New York, 1998; the contents of which is incorporated herein by reference in its entirety).
- The most widely used plasminogen activators include a recombinant form of tissue-type plasminogen activator (tPA), urokinase (UK) and streptokinase (SK), as well as a new generation of plasminogen activators selected for improved pharmacokinetics and fibrin-binding properties. All of these plasminogen activators, however, by virtue of their mechanism of action, act indirectly and require an adequate supply of their common substrate, plasminogen, at the site of the thrombus to effect lysis.
- UK and tPA convert plasminogen to plasmin directly by cleaving the Arg560-Val561 peptide bond. The resulting two polypeptide chains of plasmin are held together by two interchain disulfide bridges. The light chain of 25 kDa carries the catalytic center and is homologous to trypsin and other serine proteases. The heavy chain (60 kDa) consists of five triple-loop kringle structures with highly similar amino acid sequences. Some of these kringles contain so-called lysine-binding sites that are responsible for plasminogen and plasmin interaction with fibrin, alpha 2-antiplasmin or other proteins. SK and staphylokinase activate plasminogen indirectly by forming a complex with plasminogen, which subsequently behaves as a plasminogen activator to activate other plasminogen molecules by cleaving the arginyl-valine bond.
- Although thrombolytic drugs, such as tissue plasminogen activator (tPA), streptokinase and urokinase, have been successfully employed clinically to reduce the extent of a thrombotic occlusion of a blood vessel, it appears that serious limitations persist with regard to their use in current thrombolytic therapy. For example, because the activation of plasminogen by tPA is fibrin dependent for full proteolytic activity to be realized (Haber et al. 1989), excessive bleeding may result as a side effect of its use. Other adverse sequelae associated with the use of these thrombolytic agents include myocardial infarction, occlusive stroke, deep venous thrombosis and peripheral arterial disease.
- Additionally, the known plasminogen activators currently used suffer from several limitations that impact their overall usefulness in the elimination of a thrombus. For example, at best, the use of current thrombolytic therapy results in restored vascular blood flow within 90 min in approximately 50% of patients, while acute coronary re-occlusion occurs in roughly 10% of patients. Coronary recanalization requires on average 45 minutes or more, and intracerebral hemorrhage occurs in 0.3% to 0.7% of patients. Residual mortality is at least 50% of the mortality level in the absence of thrombolysis treatment.
- A different approach to avoid the problems associated with the systemic administration of a plasminogen activator to generate sufficient plasmin at the site of the thrombus, is to directly administer the plasmin itself to the patient.
- In U.S. Pat. No. 5,288,489, Reich et al., disclose a fibrinolytic treatment that includes parenterally introducing plasmin into the body of a patient. The concentration and time of treatment were selected to be sufficient to allow adequate active plasmin to attain a concentration at the site of an intravascular thrombus that is sufficient to lyse the thrombus or to reduce circulating fibrinogen levels. However, the necessity of generating the plasmin from plasminogen immediately prior to its introduction into the body is also disclosed.
- In contrast, U.S. Pat. No. 3,950,513 to Jenson teaches that plasmin compositions may be stabilized at pH 7.0 by including a physiological non-toxic amino acid. This method dilutes stock plasmin solutions stored at low pH with the neutralizing amino acid immediately prior to administration. There are advantages, however, in maintaining low pH of the plasmin composition as long as possible to minimize autodegradation. Ideally, the plasmin will be retained at a low pH until encountering the target fibrin.
- Yago et al. disclose plasmin compositions useful as a diagnostic reagent in U.S. Pat. No. 5,879,923. The compositions of Yago et al. comprise plasmin and an additional component which may be 1) an oligopeptide comprising at least two amino acids, or 2) at least two amino acids, or 3) a single amino acid and a polyhydric alcohol. However, the compositions of Yago et al. are formulated at a neutral pH to maintain the enzymatic activity of plasmin.
- Plasmin as a potential thrombolytic agent has numerous technical difficulties. These difficulties include the challenge of preparing pure plasmin that is free of all functional traces of the plasminogem activator used to convert plasmin from its inactive precursor, plasminogen. Preparations of plasmin are typically extensively contaminated by plasminogen activator, streptokinase or urokinase and the thrombolytic activity was, therefore, attributed to the contaminating plasminogen activators rather than to plasmin itself The contaminating plasminogen activators could also trigger systemic bleeding other than at the targeted site of thrombosis. A drawback of streptokinase containing plasmin preparations is that streptokinase can cause adverse immune reactions including fever and anaphylactic shock.
- One of the more important technical factors limiting clinical use of plasmin is that plasmin, as a serine protease with broad specificity, is highly prone to autodegradation and loss of activity. This circumstance provides severe challenges to the production of high-quality plasmin, to the stable formulation of this active protease for prolonged periods of storage prior to use, and to safe and effective administration of plasmin to human patients suffering from occlusive thrombi. Thus, there is need for a method of producing stable plasmin.
- The present invention provides for both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored in a low pH buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III by affinity chromatography with an elution at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.
- Briefly, the method for purifying plasmin comprises cleaving a plasminogen in the presence of a plasminogen activator to yield an active plasmin and removing the plasminogen activator from the active plasmin to form a plasmin solution. A low pH-buffering capacity agent can then be added to the final plasmin solution to form a reversibly inactive acidified plasmin. The final plasmin solution may be buffered to a pH of between about 2.5 to about 4.
- The plasminogen activator can be removed from the active plasmin by binding the active plasmin to an active plasmin-specific absorbent material to form a bound plasmin. One such active plasmin-specific absorbent material can comprise benzamidine. Once bound, the active plasmin can be eluted with a low pH solution to form a final plasmin solution. Plasminogen activator may also be further removed by hydrophobic interaction.
- A further method of purifying plasmin comprises cleaving plasminogen to yield an active plasmin and binding the active plasmin to an active plasmin-specific absorbent material to form a bound plasmin. The bound plasmin can be eluted with a substantially neutral amino acid to form a final plasmin solution which is substantially free of degraded plasmin. The substantially neutral amino acid can comprise an omega-amino acid and is typically filtered out of the final plasmin. The final plasmin may also be buffered with a low pH-buffering capacity agent.
- The process for the purification of plasminogen from a plasma source includes the steps of adding the plasminogen containing solution to a plasminogen-specific absorbent material and then eluting the plasminogen from the plasminogen-specific absorbent material at a pH of between about 1 to about 4. The purified plasminogen is then collected as an eluate. Additionally, the process may include methods for the purification of micro- or mini-plasmin(ogen) or other truncated or modified forms of plasmin(ogen).
- Thus, a process is now provided that successfully addresses the shortcomings of existing processes and provides distinct advantages over such processes. Additional objects, features, and advantages of the invention will become more apparent upon review of the detailed description set fourth below when taken in conjunction with the accompanying drawing figures, which are briefly described as follows.
- In the Drawings:
- FIG. 1 graphically depicts the effect of on plasminogen recovery and lipid removal from CCI filtrate I through PEG precipitation/depth filtration;
- FIG. 2 graphically depicts nephelometry data for CCI extract and the subsequent filtrates I and II;
- FIG. 3 depicts a gel of coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of CCI extract, filtrates and UF/DF retentate;
- FIG. 4 depicts a coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of
lysineSEPHAROSE 4B affinity purification of Pmg; - FIG. 5 graphically depicts a
lysineSEPHAROSE 4B chromatogram for the affinity purification of Pmg; - FIG. 6 depicts a coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of pH adjustment of the
lysineSEPHAROSE 4B eluate (Pmg) with and without epsilon amino caproic acid present; - FIG. 7 graphically represents streptokinase activation solution stability following 0.5 M NaCl, 0.25 M ε-ACA stop;
- FIG. 8 graphically represents
benzamidine SEPHAROSE 6B chromatogram for the affinity purification of SK activated Pm; - FIG. 9 depicts a coomassie stained reduced SDS-PAGE (10-20% Tris-Glycine) of
benzamidine SEPHAROSE 6B purified Pm; - FIG. 10 graphically depicts the hydrophobic interaction chromatography (
OctylSEPHAROSE 4 FF) chromatogram for the removal of streptokinase; and - FIG. 11 depicts a non-reduced SDS PAGE and anti-SK Western Blot.
- The present invention comprises both a method for producing a reversibly inactive acidified plasmin in combination with a low pH-buffering capacity agent and a method for the purification of plasminogen from a plasma source. The inactive acidified plasmin solution may also include a stabiliser in addition to being inactivated in buffered solution. The process for purifying plasminogen provides for both inactivation and removal of pathogens and the elution of the plasminogen at a low pH. The inactive acidified plasmin preparation can be used in the administration of a thrombolytic therapy.
- Purification of Plasminogen
- The present invention includes both a process for the purification of plasminogen and plasmin and concurrently, methods for the inactivation and removal of viral and Transmissible Spongiform Encephalopathies (TSE) contaminants during these processes. The starting material, plasminogen, can be purified from Cohn Fraction II+III paste by affinity chromatography on Lys-SEPHAROSE as described by Deutsch & Mertz (1970). SEPHAROSE is a trade name of Pharmacia, Inc. of New Jersey for a high molecular weight substance for the separation by gel filtration of macromolecules. The process may be performed on any plasma source, recombinant source, cell culture source or transgenic source. For example, plasma from a waste fraction derived from the purification of immunoglobulin from a chromatographic process can be used as described in commonly owned U.S. patent application Ser. No. 09/448,771, filed Nov. 24, 1999, which is incorporated by reference herein.
- Plasminogen was extracted from this waste fraction (referred to herein as the “caprylate cake I” (CCI)) over a wide range of pH. Conditions of extraction can be varied from a pH of about 3.5 to about 10.5 using a variety of buffers capable of providing a pH in this range, including citrate, acetate, tris, imidazole, histadine, HEPES and/or phosphate buffers. The extraction can occur at temperatures from about 4° C. to 37° C. and can be run for 1 to 24 hours without deleterious effect. In addition, the ionic strength can be varied by the addition of about 0.2 Molar sodium chloride without deleterious effect on the extraction of plasminogen.
- Following the extraction of plasminogen, lipid and protein impurities and TSE were reduced by precipitation with the addition polyethylene glycol (PEG), in a range of about 1 to about 10% weight/volume or the addition of about 80 to about 120 g/L ammonium sulfate. The PEG or ammonium sulfate precipitate was removed by depth filtration and the resulting solution placed on a lysine affinity resin column.
- If desired, the solubility of plasminogen may be enhanced by the addition of omega-amino acids (lysine, arginine, tranexamic acid, or epsilon amino caproic acid, or combinations or analogues thereof) after extraction of the caprylate cake I. Solubility enhancement may be accomplished with from about 0.02 M to about 1 M omega-amino acid, preferably about 0.1 M lysine appears to be sufficient. If added, the lysine is preferably removed after the PEG or ammonium sulfate precipitation and depth filtration by diafiltration and the resulting solution placed on a lysine affinity resin column. The phrase “lysine affinity resin” is used generally for affinity resins containing lysine or its derivatives or epsilon caproic acids as the ligand. The column can be eluted with a low pH solution of approximately 1 to 4.
- The protein obtained after elution from the affinity column is generally at least 80% plasminogen. The purified plasminogen is then stored at low pH in the presence of simple buffers such as glycine and lysine or omega-amino acids. Storage at low pH also provides an opportunity for viral inactivation and removal and TSE removal as determined by spiking methods. Our studies suggest that plasmin meets the most stringent requirements for 6 log clearance of non-enveloped viruses including one 4 log removal step, and 10 log clearance for enveloped viruses including two independent 4 log elimination steps. In addition to sufficient virus clearance, plasmin has greater than 6 logs of TSE infectivity removal for added safety.
- The plasminogen in solution was then activated to plasmin by the addition of a plasminogen activator, which may be accomplished in a number of ways including but not limited to streptokinase, urokinase, or the use of urokinase immobilized on resin and use of streptokinase immobilized on resin. The preferred plasminogen activator is soluble streptokinase. The addition of stabilizers such as glycerol, and omega-amino acids such as lysine, poly lysine, arginine, epsilon amino caproic acid and tranexamic acid were shown to enhance the yield of plasmin.
- Purifying Plasmin
- Plasmin was purified from unactivated plasminogen by affinity chromatography on resin with benzamidine as the ligand and elution with a neutral omega-amino acid solution or low pH solution. This step can remove essentially all degraded plasmin as well as the majority of the streptokinase.
- As a polishing step for the removal of remaining streptokinase, hydrophobic interaction chromatography at low pH is performed. Following the HIC step, the plasmin is formulated as a sterile protein solution by ultrafiltration and diafiltration and 0.22 μm filtration.
- The present method additionally includes the steps of activating plasminogen to plasmin using a plasminogen activator and then capturing the formed active plasmin on an active plasmin specific absorbent material. The bound plasmin is then eluted with a low pH buffer. The eluted plasmin is buffered with a low ph-buffering capacity agent such as an acid. Typically, the eluted plasmin is buffered to a pH of between about 2.5 to about 4.
- The low buffering capacity of the acidic buffer aids in enabling the reversibly inactivated acidified plasmin to be brought up to physiological pH quickly and then activated when administered as a thrombolytic agent. Typically, the buffer is added in a concentration at which the pH of the acidified plasmin is raised to neutral pH by adding no more than about 5 times the volume of serum to the acidified plasmin.
- Cleaving the Plasminogen to Yield an Active Plasmin
- Plasminogen can be cleaved to plasmin by using a catalytic concentration of an immobilized or soluble plasminogen activator. Plasmin, the principle fibrinolytic enzyme in mammals, is a serine protease with trypsin-like specificity that is derived from the inactive zymogen precursor plasminogen circulating in plasma. Plasminogen itself is a 790 amino acid polypeptide having an N-terminus glutamate residue. Plasminogen activators such as soluble streptokinase, tissue plasminogen activator (tPA) or urokinase will cleave the single-chain plasminogen molecule to produce active plasmin at the Arg560-Val561 peptide bond. The resulting two polypeptide chains of plasmin are held together by two interchain disulfide bridges. The light chain of 25 kDa carries the catalytic center and is homologous to trypsin and other serine proteases. The heavy chain (60 kDa) consists of five triple-loop kringle structures with highly similar amino acid sequences. Some of these kringles contain so-called lysine-binding sites that are responsible for plasminogen and plasmin interaction with fibrin, alpha2-antiplasmin or other proteins.
- The activation of plasminogen can occur at about 4° C. to about 37° C. and typically takes between about 2 to 24 hours. The plasminogen can be cleaved in the presence of stabilisers such as omega-amino acids and glycerol. The omega-amino acids can include lysine, epsilon amino caproic acid, tranexamic acid, poly lysine, arginine and combinations or analogues thereof. Upon the completion of the activation, the plasmin solution can be filtered and further stabilised for several days at neutral pH by the addition of omega-amino acids and sodium chloride and applied to benzamidine-SEPHAROSE.
- Removing Plasminogen Activator and Impurities
- The active plasmin formed from the cleaving of the plasminogen can then be bound to an active plasmin specific absorbent to substantially remove the plasminogen activator. Since the protein of interest is an active serine protease with trypsin-like specificity, benzamidine may be used as an active plasmin specific absorbent that allows for the capture of the active plasmin. Other active plasmin specific absorbents having similar properties as benzamidine may also be used. The benzamidine can be immobilized in a solid support medium. The solid support medium can be a resin or SEPHAROSE. Additionally, hydrophobic interaction may be used to further remove the plasminogen activator.
- More specifically, the cleaved plasminogen is typically contained in a solution of amino acids, sodium chloride and glycerol, which allows for stability of the solution for several days at neutral pH before it is applied to a benzamidin-SEPHAROSE column equilibrated with about 0.05 M Tris, pH 8.5, 0.5 M NaCl. The column is typically run at 4° C. The front portion of the non-bound peak contains high-molecular weight impurities, with the rest of the nonbound peak being represented by residual non-activated plasminogen and by inactive autodegradation products of plasmin.
- The bound plasmin can then be eluted with an acid buffer or with a substantially neutral omega-amino acid. The plasmin bound to benzamidine-SEPHAROSE can be eluted with an acidic buffer such as glycine buffer. When a substantially neutral pH omega-amino acid is used to elute the bound plasmin the final eluted plasmin solution can be substantially free of degraded plasmin. Typically, the substantially neutral pH amino acid has a pH of value of between about 65 to about 8.5. Examples of neutral omega-amino acids include lysine, epsilon amino caproic acid, tranexamic acid, poly lysine, arginine, and analogues and combinations thereof.
- Buffering the Plasmin Solution with a Low pH-Buffering Capacity Agent
- The eluted plasmin can be buffered with a low pH-buffering capacity agent. The low pH-buffering capacity agent typically comprises a buffer of either an amino acid, a derivative of at least one amino acid, an oligopeptide which includes at least one amino acid, or a combination of the above. Additionally the low pH-buffering capacity agent can comprise a buffer selected from acetic acid, citric acid, hydrochloric acid, carboxcylic acid, lactic acid, malic acid, tartaric acid, benzoic acid, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, alanine, aspartic acid, derivatives or combinations thereof. The buffer can be present in the reversibly inactive acidified plasmin at a concentration at which the pH of the acidified plasmin is raised to neutral pH by adding no more than about 4 to 5 times the volume of serum to the composition.
- The concentration of plasmin in the buffered solution can range from about 0.01 mg/ml to about 50 mg/ml of the total solution. The concentration of thebuffer can range from about 1 nM to about 50 mM. Of course these ranges may be broadened or narrowed depending upon the buffer chosen, or upon the addition of other ingredients such as additives or stabilizing agent& The amount of buffer added is typically that which will bring the reversibly inactive acidified plasmin solution to have a pH between about 2.5 to about 4.
- Further Stabilizing the Inactive Acidified Plasmin Solution
- The reversibly inactive acidified plasmin solution may be further stabilized by the addition of a stabilizing agent such as a polyhydric alcohol, pharmaceutically acceptable carbohydrates, salts, glucosamine, thiamine, niacinamide, or combinations thereof. The stabilizing salts can be selected from the group consisting of sodium chloride, potassium chloride, magnesium chloride, calcium chloride and combinations thereof. Sugars or sugar alcohols may also be added, such as glucose, maltose, mannitol, sorbitol, sucrose, lactose, trehalose, and combinations thereof.
- Concentrations of carbohydrate added to stabilize the reversibly inactive acidified plasmin solution include a range from about 0.2% w/v to about 20% w/v. Ranges for a salt, glucosamine, thiamine, niacinamide and their combinations can range from about 0.01 M to about 1 M.
- The plasmin being formulated in a buffered acidified water has been found to be extremely stable. It can be kept in this form for months without any loss of activity or the appearance of degradation products of a proteolytic or acidic nature. At 4° C., plasmin is stable for at least nine months. Even at room temperature, plasmin is stable for at least two months. Long-term stability at room temperature is important because it would make this formulation compatible with long regimens of thrombolytic administration. For example, 36 hours administration of thrombolytics such as tissue plasminogen activator or urokinase is common in treatment of peripheral arterial occlusions.
- The ability of a buffered acidified plasmin to become fully active upon transfer to physiological pH is evidenced by its activity in the caseinolytic assay and also in the I125-fibrin-labelled clot lysis assays. Both of these assays are performed at pH 7.4, and there was complete recovery of plasmin activity during the change of pH and passing through the iso-pI point (pH 5-5.5). This is because plasmin is formulated in a non-buffered solvent and when added to a buffered solution (either PBS of plasma) it adopts the neutral pH instantly and the precipitation that usually accompanies the slow passage through the iso-pI point, does not occur.
- A feature of the active plasmin as used in the present invention is the maintenance of the plasmin in an acidic buffer and its formulation in acidified water, providing a pure and stable active plasmin. Its efficacy was demonstrated in in vitro assays and in an in vivo rabbit jugular vein thrombolysis model unified, substantially purified or partially purified enzyme such as, but not limited to, plasmin or any composition containing plasmin that is within the scope of the present invention.
- A description of a method of treating thrombolysis and related ailments employing aspects of the claimed invention is disclosed in the application entitled “Method of Thrombolysis by Local Delivery of Reversibly Inactivated Acidified Plasmin”, attorney docket number B185 1020 and commonly assigned and filed contemporaneously with the instant application, and which is incorporated herein by reference in its entirety. Additionally, compositions made in accordance with the claimed invention are disclosed in the application entitled “Reversibly Inactivated Acidified Plasmin”, attorney docket number B185 1030 and commonly assigned and filed contemporaneously with the instant application, and which is incorporated herein by reference in its entirety.
- The following examples are given only to illustrate the present process and are not given to limit the invention. One skilled in the art will appreciate that the examples given only illustrate that which is claimed and that the present process is only limited in scope by the appended claims.
- Caprylate Cake I (CCI) Extraction and Lipid Reduction by PEG Precipitation and Filtration
- Caprylate cake I (CCI) is a fraction resulting from a
pH 5 caprylate precipitation of resuspended Fraction II+III in the IGIV-C process. Plasminogen (Pmg) is extracted from the CCI by solubilizing at a cake:buffer ratio of about 1:10 for 2 to 3 hours at 4° C. with mixing. While several extraction solutions were investigated, the current method was performed with 100 mM Tris pH 10.5 to maintain the pH at or above neutral; a condition favorable to Pmg solubilization from the CCI. Table 1 depicts the extraction solutions investigated along with their final extract pH and Pmg potency.TABLE 1 CCI Extraction Solutions and Their Resulting Final Extract pHs and Pmg Activities. Extraction Solution Final Extract pH Pmg (IU/mL) 0.1 M Tris pH 10.5 9.2-9.5 1.77 0.2 M Tris pH 7.5 7.5 2.06 0.05 M Citrate, 0.2 Mε-ACA, 6.0 1.49 0.4 M NaCl pH 6.5 0.15 M Citrate pH 8.3 6.7 1.21 0.4% Acetic Acid pH 3.5 3.5 0.05 - Following 2 to 3 hours of extraction, the temperature of the extractis adjusted to 20° C. and the pH to 7.5. Table 2 shows the Pmg yield, based on nephelometry, from Clarified Plasma Pool through Fraction II+III and CCI Extract.
TABLE 2 Step and Process Yields for Pmg from Clarified Plasma Pool to CCI Extract. % Pmg % Pmg Process Cohn Fraction mg Pmg/g (SD), n Step Yield Yield Clarified Plasma Pool 0.124 (0.013), 33 Fraction II + III 0.143 (0.024), 30 65.6 CCI Extract (post L-lysine) 0.145 (0.01), 7 101 66.3 - Only about 66% of the Pmg in plasma tracks to Fraction II+III while virtually all of the Pmg found in the resuspended Fraction II+III precipitates to and is extracted from CCI. Extraction of CCI in Tris pH 10.5, final CCI Extract pH of 9.2-9.5, solubilizes all of the Pmg found in the CCI.
- The addition of lysine derivatives (100 mM L-lysine, 50 mM epsilon amino caproic acid (EACA)) increases the solubility of Pmg in the CCI Extract resulting in increased recoveries during subsequent PEG precipitation and filtration steps as illustrated in FIG. 1.
- Reduction of lipid is achieved through precipitation by the addition of PEG 3350 to 3% -4% w/w. As mentioned previously, the addition of L-lysine to 100 mM prior to PEG addition is necessary to maintain high Pmg recovery in the PEG filtrate, or about 90%. Without the addition of lysine, only about 25% of the Pmg is recovered in the PEG filtrate (FIG. 1). The PEG precipitation proceeds for 1 to 2 hours at 20° C. with mixing. Filter aid is added to 4% w/w and mixed prior to depth filtration through a CUNO 30SP followed by further clarification with 0.5 micron and 0.22 micron filters.
- FIG. 1 shows the lipid content, determined by cholesterol and triglycerides concentration, is reduced by 60-70% following PEG precipitation and filtration (CCI Filtrate I). The CCI Filtrate I is diluted 1:1 with phosphate buffered saline pH 7.5 and held at 20° C. for 1 to 2 hours as precipitation often continues following filtration. The CCI Filtrate I is filtered through 0.5 μm and 0.22 μm filters to remove any additional precipitate; CCI Filtrate II. Nephelometry data for CCI Extract and CCI Filtrates I and II are illustrated in FIG. 2. Note that fibrinogen and apolipoprotein A-1 concentrations are reduced following PEG precipitation.
- The CCI Filtrate II is diafiltered by tangential flow filtration (TFF) against phosphate buffered saline pH 7.5 to reduce the L-lysine concentration such that it will not act as a competitive inhibitor for Pmg binding to the lysine affinity resin. Experiments were performed to illustrate the necessity of lysine removal. Loading the CCI Filtrate II directly onto a lysine affinity resin without reduction in soluble lysine concentration, results in the capture and release of about 4% of the Pmg activity. Diluting the CCI Filtrate II 1:1 with TBS (10 mM Tris, 150 mM NaCl pH 7.5) still resulted in capture and release of only about 5% of the Pmg activity. Following 5 volumes of diafiltration to reduce the lysine concentration, about 22% of the Pmg activity was captured and released from the lysine affinity resin (in retrospect, the column was overloaded by about 50%).
- Constant volume diafiltration was performed by tangential flow filtration (TFF) against 5 volumes phosphate buffered saline pH 7.5 using a 30 kDa molecular weight cutoff membrane. Following diafiltration, the protein solution was concentrated by ultrafiltration to 4 to 5 A280/mL. Pmg recoveries in the UF/DF retentate, by nephelometry, averaged 84% (±1, n=3). FIG. 3 shows reduced SDS PAGE for each of the process intermediates discussed thus far. The data in FIGS. 2 and 3 illustrate the complexity and heterogeneity of the CCI Extract and subsequent Filtrates.
- Purification of Pmg by Lysine Affinity Chromatography:
- The purpose of lysine affinity chromatography is to purify Pmg, which represents from about 3 to 5% of the total protein in the diafiltered CCI Filtrate II. The DF CCI Filtrate II was applied to a Lysine-
SEPHAROSE 4B (Amersham Pharmacia #17-0690-01) column equilibrated with 0.01 M NaH2PO4, 0.15 M NaCl pH 7.5, at 3.5-4.0 A280/mL resin. Unbound proteins were washed through the column with the equilibration buffer and the resin was then washed with 0.01 M NaH2PO4, 0.5 M NaCl pH 7.5 to remove nonspecifically bound protein; no protein was removed. Bound protein, Pmg, was eluted with 0.1 M Glycine, 0.03 M Lysine pH 3.0 and collected with mixing to maintain low pH. FIGS. 4 and 5 show SDS PAGE analysis and the chromatogram of the lysine affinity purification of Pmg, respectively. The resin was cleaned sequentially with 0.1 N NaOH and 2.0 M NaCl, 0.1% Triton X-100 and stored in 20% ethanol. Table 3 shows Pmg step yield by nephelometry and purity by reduced SDS PAGE.TABLE 3 Lysine Affinity Chromatography Pmg Step Yield and Purity Process Intermediate Step Yield % Pmg Purity % Lysine- SEPHAROSE 4B75.7 85.9 Eluate - Viral Inactivation and Removal and TSE Removal
- Nanofiltration
- The optimal placement of a nanofiltration step during the Plasmin process, along with determining the optimal conditions for pathogens removal from Pmg lysine affinity eluate (Pmg) for a particular nanofiltration scheme was tested. Pmg was spiked with PPV or BVDV and filtered through a PALL DV20 filter membrane. All runs were performed with 50 ml starting material (0.3 mg/ml Pmg), 30 psi constant pressure, pH 3.4 and room temperature. The challenge solution was pre-filtered through 0.22 μm prior to nanofiltration. The determining factors for the optimal conditions for removal of different pathogens by nanofiltration deal mainly with the attainment of a minimum of 4 log infectivity removal of known pathogens, percent product recovery, percent potency remaining, product concentration and product pH. We detected, that PPV and BVDV clearance was >4 log10 TCID50. The nanofiltration step has also the capability of removing greater than 4 log of TSE. All product recoveries obtained in the study were ≧95% with no substantial change in Pmg activity.
- Caprylate Viral Inactivation.
- Since caprylate inactivation is very much pH dependent and more efficacious under acidic pH conditions, it was logical to study virus inactivation by caprylate at the low pH lysine affinity chromatography elution step. We used BVDV as a model enveloped virus to study caprylate virucidal activity in lysine affinity eluate. Complete BVDV inactivation, resulting in >4.4 log10 reduction, was detected at the lysine affinity column eluate with 3 mM caprylate at pH 3.4 during 30 min of incubation at room temperature in the presence of 1.5 mg/ml Pmg. In the absence of product, complete BVDV inactivation (≧4.7 log10 reduction) was also achieved with 3 mM caprylate after 30 minutes at pH 3.4. No visible precipitation was observed during the caprylate treatment suggesting that the product and virus spike remain soluble and are not being precipitated by the caprylate. The impact of the added caprylate on product recovery or potency following lysine affinity column chromatography was minimal.
- PEG Precipitation
- We have investigated the effect of PEG on TSE removal. The clarification and removal of lipids achieved by depth filtration and 3% PEG precipitation of the Caprylate Cake I Extract resulted in greater than 2 log10 of TSE removal.
TABLE 4 Total Virus/TSE clearance across Plasmin process Step BVDV PPV TSE Nanofiltration >4 log 4 log 4 log 3 mM Caprylate >4 log <1 log <1 log Lysine Affinity 3.3 log 2.5 log pending PEG precipitation <1 <1 2-3 logs Total clearance >12 >6 >6 - Streptokinase (SK) Activation of Pmg to Pm (Pm):
- The addition of SK to the purified Pmg solution effects the conversion of Pmg to Pm. The lysine affinity column eluate pH 3.4 is concentrated by TFF to 2 mg/mL through a 30 kD molecular weight cutoff membrane. The Pmg solution temperature is ramped down to 4° C. and a Pmg stabilizer, EACA, is added to a final concentration of 20 mM to protect Pmg against damage during pH adjustment from 3.4 to 7.5. Without the addition of EACA, a 67 kDa species appears following the pH swing. The presence of EACA during pH adjustment results in decreased Pmg degradation as compared to pH adjustment without EACA (FIG. 6). Once the pH is adjusted to 7.5, the Pmg solution is diluted 1:1 with 20% glycerol, 4° C., to achieve a final condition of 1 mg Pmg/mL 0.05 M glycine, 0.015 M L-lysine, 0.01 M EACA, 10% glycerol pH 7.5. These conditions have been optimized for minimizing Pm autodegradation. SK is added to this solution at a 100:1 Pmg:SK molar ratio. The SK reaction mixture is mixed at 4° C. for 16 hours to allow activation of Pmg to Pm. The average relative percent purity, as determined by reduced SDS PAGE, of each of 4 groups of protein species (Pmg, Pm HC, Pm LC and impurities/clipped Pm) from 14 SK activation reactions are listed in Table 5.
TABLE 5 Relative Average % of Pmg, Pm (HC, LC) and Impurities/ Clipped Pm by Reduced SDS PAGE Following SK Activation; n = 14. Protein Average % Purity SD Pmg 20.3 5.3 Pm 68.5 4.4 Pm Heavy Chain 49.0 2.9 Pm Light Chain 19.4 1.5 Impurities/Clipped Pm 11.3 1.8 - The data shows that the SK activation is reproducible and results in only about 11% clipped Pm/impurities while activation of Pmg to Pm is about 80%. To stop the activation and Pm autodegradation reactions, NaCl and EACA are added to final concentrations of 0.5 M and 0.25 M, respectively. This solution is stable with respect to Pm integrity, for at least 4 days at 4° C. FIG. 7 illustrates that there is no change in the Pm purity or Pm autodegradation (Other) over this time period.
- Purification of Pm by Benzamidine Affinity Chromatography:
- The purpose of benzamidine affinity purification is the separation of unactivated Pmg and impurities, including Pm degradation products, from active Pm. The stable SK activation solution, pH adjusted to 8.5 in 0.05 M glycine, 0.015 M L-lysine, 0.25 M EACA, 0.5 M NaCl, 10% glycerol, is applied to a
Benzamidine SEPHAROSE 6B (Amersham Pharmacia #17-0568-01) column equilibrated with 50 mM Tris, 500 mM NaCl, pH 8.5. The Pm, both clipped and intact, is captured by the affinity resin while the aforementioned impurities flow through the column. The column is washed with the equilibration buffer until the absorbance at 280 nm reaches baseline. The bound Pm is then eluted in either one of two ways: 1) removing the resin and eluting in batch format with 0.1 M Glycine, 0.03 M Lysine pH 3.4; 2) eluting in a column format with 1 M EACA pH 7.5. Elution with EACA pH 7.5 removes only the intact Pm while damaged Pm remains bound to the resin. A step to strip all remaining protein. FIG. 8 shows a typical column format, EACA elution profile. The batch elution profile consists only of the unbound protein peak as the resin is then removed from the column for Pm elution. The Pm captured and eluted from the affinity resin is 87-91% intact (non-autodegraded) as illustrated in FIG. 9 and ≧99% total Pm. The elution of Pm from the benzamidine resin with EACA was unexpected as lysine derivatives such as EACA interact with the heavy chain of Pm while benzamidine interacts with the light chain. - Removal of the Pmg Activator SK
- The purpose of these steps is to remove the Pmg activator SK such that the only remaining fibrin clot dissolution activity is that of Pm. The benzamidine affinity step removes >99% of the SK from the Pm as is illustrated in Table 6.
TABLE 6 SK removal, as determined by ELISA, by benzamidine affinity chromatography and hydrophobic interaction chromatography. Plasmin Process Step Streptokinase (ng/mL) SK activation 1930.1 Benzamidine-SEPHAROSE unbound 1549.5 Benzamidine-SEPHAROSE eluted Pm 1.9 HIC Unbound Pm 0.7 HIC NaOH strip (SK) 1.3 Final Formulation Pm <0.5 - The hydrophobic interaction step using
Octyl SEPHAROSE 4 FF (Amersham Pharmacia #17-0946-02) acts as a polishing step to remove essentially any remaining SK. The final sterile Pm product has no detectable SK by ELISA. The 1 M EACA eluate pH 7.5, from the benzamidine affinity column, is adjusted to pH 3.4 and (NH4)2SO4 is added to a final concentration of 0.1 M. This acts as the protein load for the Octyl-SEPHAROSE 4 FF column. The column is equilibrated with 0.1 M (NH4)2SO4, 0.1 M Glycine, 30 mM Lysine pH 3.4. Pm flows through the column while SK binds to the column and is separated from Pm. The captured SK is removed from the resin along with 0.1 to 1.0 N NaOH. FIG. 9 is an Octyl-SEPHAROSE 4 FF chromatogram from a proof of principle experiment. Pmg and SK were mixed at a 2:1 Pmg:SK molar ratio and subjected to Octyl-SEPHAROSE 4 FF chromatography. The high levels of SK were used so it could be tracked throughout the chromatographic cycle using an anti-SK western blot. FIG. 10 illustrates the removal of SK from the Pm by SDS PAGE and anti-SK western blot. The SK standard (panels A and B; lane 1) migrates true to its molecular weight of 47 kDa. Once mixed with Pmg, the SK is modified and migrates faster and as several species. There is no detectable SK in the unbound protein fraction, which contains the bulk of the Pm, by anti-SK western blot (panel B; lane 3). - Results for final sterile preparations of Pm purified by benzamidine affinity and HIC chromatographies, as described above, are listed in Table 7.
TABLE 7 Relative Average % Purity of Pm (HC, LC) by Reduced SDS PAGE Following HIC; n = 2. Protein Average % Purity Pmg 0.0 Pm 95.5 Pm Heavy Chain 66.5 Pm Light Chain 29.0 Impurities/Clipped Pm 4.5 - While specific embodiments have been set forth as illustrated and described above, it is recognized that variations may be made with respect to disclosed embodiments. Therefore, while the invention has been disclosed in various forms only, it will be obvious to those skilled in the art that many additions, deletions and modifications can be made without departing from the spirit and scope of this invention, and no undue limits should be imposed except as set forth in the following claims.
Claims (41)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/143,156 US20020192794A1 (en) | 1999-11-13 | 2002-05-10 | Process for the production of a reversibly inactive acidified plasmin composition |
US10/692,105 US7544500B2 (en) | 1999-11-13 | 2003-10-23 | Process for the production of a reversibly inactive acidified plasmin composition |
US12/399,438 US8268782B2 (en) | 1999-11-13 | 2009-03-06 | Composition and method for preparing plasminogen |
US13/761,676 US20130164815A1 (en) | 1999-11-13 | 2013-02-07 | Process for the production of a reversibly inactive acidified plasmin composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/438,331 US6355243B1 (en) | 1999-11-13 | 1999-11-13 | Method of thrombolysis by local delivery of active plasmin |
PCT/US2000/042143 WO2001036611A1 (en) | 1999-11-13 | 2000-11-13 | Process for the production of a reversibly inactive acidified plasmin composition |
US10/143,156 US20020192794A1 (en) | 1999-11-13 | 2002-05-10 | Process for the production of a reversibly inactive acidified plasmin composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/042143 Continuation WO2001036611A1 (en) | 1999-11-13 | 2000-11-13 | Process for the production of a reversibly inactive acidified plasmin composition |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/692,105 Continuation-In-Part US7544500B2 (en) | 1999-11-13 | 2003-10-23 | Process for the production of a reversibly inactive acidified plasmin composition |
US13/761,676 Continuation US20130164815A1 (en) | 1999-11-13 | 2013-02-07 | Process for the production of a reversibly inactive acidified plasmin composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020192794A1 true US20020192794A1 (en) | 2002-12-19 |
Family
ID=23740237
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/438,331 Expired - Lifetime US6355243B1 (en) | 1999-11-13 | 1999-11-13 | Method of thrombolysis by local delivery of active plasmin |
US10/143,112 Abandoned US20030012778A1 (en) | 1999-11-13 | 2002-05-10 | Reversibly inactivated acidified plasmin |
US10/143,156 Abandoned US20020192794A1 (en) | 1999-11-13 | 2002-05-10 | Process for the production of a reversibly inactive acidified plasmin composition |
US12/197,617 Expired - Fee Related US7871608B2 (en) | 1999-11-13 | 2008-08-25 | Reversibly inactivated acidified plasmin |
US13/761,684 Expired - Fee Related US9879246B2 (en) | 1999-11-13 | 2013-02-07 | Reversibly inactivated acidified plasmin composition |
US13/761,676 Abandoned US20130164815A1 (en) | 1999-11-13 | 2013-02-07 | Process for the production of a reversibly inactive acidified plasmin composition |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/438,331 Expired - Lifetime US6355243B1 (en) | 1999-11-13 | 1999-11-13 | Method of thrombolysis by local delivery of active plasmin |
US10/143,112 Abandoned US20030012778A1 (en) | 1999-11-13 | 2002-05-10 | Reversibly inactivated acidified plasmin |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/197,617 Expired - Fee Related US7871608B2 (en) | 1999-11-13 | 2008-08-25 | Reversibly inactivated acidified plasmin |
US13/761,684 Expired - Fee Related US9879246B2 (en) | 1999-11-13 | 2013-02-07 | Reversibly inactivated acidified plasmin composition |
US13/761,676 Abandoned US20130164815A1 (en) | 1999-11-13 | 2013-02-07 | Process for the production of a reversibly inactive acidified plasmin composition |
Country Status (16)
Country | Link |
---|---|
US (6) | US6355243B1 (en) |
EP (4) | EP1232252B1 (en) |
JP (3) | JP4988115B2 (en) |
AT (2) | ATE431401T1 (en) |
AU (3) | AU784534B2 (en) |
BE (1) | BE2013C050I2 (en) |
CA (3) | CA2389345C (en) |
CY (3) | CY1108639T1 (en) |
DE (3) | DE60040345D1 (en) |
DK (2) | DK1232252T3 (en) |
ES (3) | ES2326616T3 (en) |
FR (1) | FR13C0041I2 (en) |
LU (1) | LU92255I2 (en) |
NL (1) | NL300603I2 (en) |
PT (2) | PT1232254E (en) |
WO (3) | WO2001036611A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116676A1 (en) * | 2002-09-30 | 2004-06-17 | Hotta Joann | Methods for removal of contaminants from blood product solutions |
US20050118158A1 (en) * | 2002-12-06 | 2005-06-02 | Thromb-X Nv | Pharmacological vitreolysis |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
WO2006120423A1 (en) * | 2005-05-09 | 2006-11-16 | Prometic Biosciences Ltd. | Affinity adsorbents for plasminogen |
US20070134231A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes and compositions thereof |
US20070134230A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes |
WO2009149199A3 (en) * | 2008-06-04 | 2010-04-01 | Talecris Biotherapeutics, Inc. | Composition, method and kit for preparing plasmin |
US9206410B2 (en) | 2009-03-03 | 2015-12-08 | Grifols Therapeutics Inc. | Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544500B2 (en) * | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
US7308303B2 (en) * | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
SI1561756T1 (en) | 2002-09-11 | 2016-02-29 | Chugai Seiyaku Kabushiki Kaisha | Method of purifying protein |
PT1740698E (en) | 2004-04-22 | 2010-11-02 | Talecris Biotherapeutics Inc | Recombinantly modified plasmin |
JP2007068497A (en) * | 2005-09-09 | 2007-03-22 | Nihon Pharmaceutical Co Ltd | Method for purifying plasmin |
US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
US20070212358A1 (en) * | 2006-03-10 | 2007-09-13 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
EP2051732A4 (en) * | 2006-07-26 | 2009-10-21 | Diamedica Inc | Methods of diagnosis and treatment for metabolic disorders |
EP2220221B1 (en) | 2007-11-29 | 2014-12-31 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
TWI395593B (en) | 2008-03-06 | 2013-05-11 | Halozyme Inc | In vivo temporal control of activatable matrix-degrading enzymes |
EP2435562A1 (en) | 2009-05-26 | 2012-04-04 | Biolex Therapeutics, Inc. | Compositions and methods for production of aglycosylated plasminogen |
MX2012000475A (en) | 2009-07-10 | 2012-03-26 | Thrombogenics Nv | Variants of plasminogen and plasmin. |
ES2534911T3 (en) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Use of plasmin for the treatment of filtration failure after trabeculectomy |
CA2789667C (en) * | 2010-03-04 | 2019-04-16 | Grifols Therapeutics Inc. | Infusion catheter having an occlusion component |
JPWO2012036140A1 (en) * | 2010-09-14 | 2014-02-03 | 株式会社カネカ | Affinity carrier for purifying or removing a protein or peptide having a kringle sequence, and purification method and removal method using the same |
US9121014B2 (en) | 2011-01-05 | 2015-09-01 | ThromboGenies NV | Plasminogen and plasmin variants |
CN102225197B (en) * | 2011-06-13 | 2013-03-27 | 陕西精健新星生物医药有限公司 | Application and extraction method of acrosin |
AU2012296884B2 (en) | 2011-08-12 | 2015-02-05 | Thrombogenics N.V. | Plasminogen and plasmin variants |
WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
SI2854841T1 (en) | 2012-06-04 | 2017-06-30 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
US9085211B2 (en) * | 2012-09-13 | 2015-07-21 | GM Global Technology Operations LLC | Top mount for strut |
JP5868931B2 (en) * | 2013-12-05 | 2016-02-24 | 日本食品化工株式会社 | Method for stabilizing water-soluble dietary fiber, stabilized water-soluble dietary fiber composition, and method for producing the same |
EP3116443A4 (en) * | 2014-03-11 | 2017-12-06 | Valdemar Portney | Presbyopia correcting wireless optical system |
JP6636456B2 (en) | 2014-05-06 | 2020-01-29 | ダイアシス ダイアグノスティック システムズ ゲーエムベーハーDiasys Diagnostic Systems Gmbh | Enzymatic quantification of HbA1c |
CN106265544B (en) * | 2016-10-09 | 2019-06-04 | 瑞阳制药有限公司 | Levo-carnitine for injection composition and preparation method thereof |
JP2020510023A (en) | 2017-03-09 | 2020-04-02 | ダイアメディカ, インコーポレイテッド | Tissue kallikrein 1 dosage form |
CN106913534A (en) * | 2017-04-27 | 2017-07-04 | 武汉真福医药股份有限公司 | A kind of freeze drying powder injection and its preparation technology based on recombination bacillus subtilis fibrinolysin |
CN107760662B (en) * | 2017-11-01 | 2021-06-15 | 国药集团武汉血液制品有限公司 | Preparation method of human fibrinolytic enzyme |
CN107802828B (en) * | 2017-11-29 | 2018-09-11 | 广东天普生化医药股份有限公司 | A kind of kallikrein injection |
Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3434929A (en) * | 1966-07-12 | 1969-03-25 | American Cyanamid Co | Process for purifying plasmin |
US3950513A (en) * | 1965-12-03 | 1976-04-13 | Novo Terapeutisk Laboratorium A/S | Process of stabilizing therapeutically useful plasmin solutions |
US3950223A (en) * | 1972-12-07 | 1976-04-13 | Ajinomoto Co., Inc. | Stabilizing and enhancing urokinase activity |
US4082612A (en) * | 1976-09-24 | 1978-04-04 | Michael Reese Research Foundation | Plasminogen activator complex |
US4177262A (en) * | 1974-12-17 | 1979-12-04 | Choay S.A. | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots |
US4361653A (en) * | 1980-07-03 | 1982-11-30 | The Green Cross Corporation | Plasminogen preparations |
US4361652A (en) * | 1980-01-25 | 1982-11-30 | The Green Cross Corporation | Method for stabilizing plasminogen |
US4442213A (en) * | 1981-05-14 | 1984-04-10 | Behringwerke Aktiengesellschaft | Process for the preparation of plasminogen and plasminogen thus prepared |
US4446316A (en) * | 1980-12-31 | 1984-05-01 | Vsesojuzny Kardiologichesky Nauchny Tsentr | Dextran derivative of fibrinolysin |
US4462980A (en) * | 1981-01-05 | 1984-07-31 | Novo Industri A/S | Stabilized plasmin compositions and method for preparation thereof |
US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
US4663146A (en) * | 1983-07-29 | 1987-05-05 | Codon Genetic Engineering Laboratories | Methods and compositions for the diagnosis of bloodclots using plasminogen activator |
US4774087A (en) * | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
US4908204A (en) * | 1983-12-24 | 1990-03-13 | Beecham Group P.L.C. | Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof |
US5024829A (en) * | 1988-11-21 | 1991-06-18 | Centocor, Inc. | Method of imaging coronary thrombi |
US5068106A (en) * | 1987-06-05 | 1991-11-26 | Behringwerke Aktiengesellschaft | t-PA solution of high concentration and use of the solution in human and veterinary medicine |
US5112609A (en) * | 1985-05-28 | 1992-05-12 | Burroughs Wellcome Co. | Acidic formulations of t-PA |
US5165912A (en) * | 1989-08-18 | 1992-11-24 | Novo Nordisk A/S | Method for the detection of fibrinolytic activity |
US5288489A (en) * | 1991-08-28 | 1994-02-22 | Orion Therapeutic Systems, Inc. | Fibrinolysis and fibrinogenolysis treatment |
US5290692A (en) * | 1991-03-26 | 1994-03-01 | Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry | Bioadaptable porous crystalline glass containing an immobilized fibrinolytic enzyme for dissolving blood clots |
US5304383A (en) * | 1990-10-11 | 1994-04-19 | Immuno Aktiengesellschaft | Pharmaceutical preparation based on Lys-plasminogen |
US5328996A (en) * | 1989-03-29 | 1994-07-12 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
US5407678A (en) * | 1993-09-01 | 1995-04-18 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Petroleum jelly cream |
US5472692A (en) * | 1993-07-02 | 1995-12-05 | New England Deaconess Hospital Corporation | Pro-urokinase mutants |
US5587291A (en) * | 1992-04-14 | 1996-12-24 | Berbi Gesellschaft M.B.H. | Method for the determination of plasmin α2 -antiplasmin complexes and the use of this method as a mean of determining changes in the fibrinolytic system |
US5728674A (en) * | 1993-11-05 | 1998-03-17 | Zymogenetics, Inc. | Inhibition of blood coagulation by human-kunitz-type inhibitors |
US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
US5776452A (en) * | 1994-03-30 | 1998-07-07 | Immuno Aktiengesellschaft | Thrombosis agent |
US5879923A (en) * | 1995-06-26 | 1999-03-09 | Daiichi Pure Chemicals Co., Ltd. | Stable plasmin solution |
US5928218A (en) * | 1994-12-16 | 1999-07-27 | Gelbfish; Gary A. | Medical material removal method and associated instrumentation |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6207066B1 (en) * | 1996-07-23 | 2001-03-27 | Nuvue Technologies, L.L.C. | Method for purification of a blood component |
US20010004256A1 (en) * | 1999-12-21 | 2001-06-21 | Satoshi Iwata | Display system, display control method and computer readable medium storing display control program code |
US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
US20020091737A1 (en) * | 2000-11-01 | 2002-07-11 | Markel Steven O. | System and method for rules based media enhancement |
US6479253B1 (en) * | 1996-11-07 | 2002-11-12 | Heska Corporation | Serine protease inhibitor nucleic acid molecules and uses thereof |
US20030093423A1 (en) * | 2001-05-07 | 2003-05-15 | Larason John Todd | Determining a rating for a collection of documents |
US20040030795A1 (en) * | 2002-08-07 | 2004-02-12 | International Business Machines Corporation | System, method and program product for inserting targeted content into a portlet content stream |
US20040268228A1 (en) * | 2003-06-19 | 2004-12-30 | Microsoft Corporation | Framework for creating modular web applications |
US20050108271A1 (en) * | 2003-11-13 | 2005-05-19 | St. Jude Children's Research Hospital, Inc. | System and method for defining and collecting data in an information management system having a shared database |
US6963826B2 (en) * | 2003-09-22 | 2005-11-08 | C3I, Inc. | Performance optimizer system and method |
US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US6969515B2 (en) * | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US7015911B2 (en) * | 2002-03-29 | 2006-03-21 | Sas Institute Inc. | Computer-implemented system and method for report generation |
US7027051B2 (en) * | 2001-06-29 | 2006-04-11 | International Business Machines Corporation | Graphical user interface for visualization of sampled data compared to entitled or reference levels |
US20070038934A1 (en) * | 2005-08-12 | 2007-02-15 | Barry Fellman | Service for generation of customizable display widgets |
US7181417B1 (en) * | 2000-01-21 | 2007-02-20 | Microstrategy, Inc. | System and method for revenue generation in an automatic, real-time delivery of personalized informational and transactional data |
US7496852B2 (en) * | 2006-05-16 | 2009-02-24 | International Business Machines Corporation | Graphically manipulating a database |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3136703A (en) | 1958-04-22 | 1964-06-09 | Ortho Pharma Corp | Method for obtaining fibrinolysin |
US3066079A (en) * | 1959-09-18 | 1962-11-27 | American Cyanamid Co | Methods for purifying plasminogen |
DK98833C (en) † | 1961-04-25 | 1964-05-25 | Novo Terapeutisk Labor As | Method for stabilizing therapeutically useful plasmin solutions. |
FR2254316B1 (en) * | 1973-12-18 | 1977-04-22 | Choay Sa | |
US3865692A (en) | 1974-01-11 | 1975-02-11 | Abbott Lab | Method for making highly potent plasminogen |
US4259448A (en) * | 1978-01-03 | 1981-03-31 | Nippon Soda Company, Ltd. | Protein adsorbent and process for the purification of urokinase |
US4418052A (en) | 1980-08-12 | 1983-11-29 | Wong Dennis W | Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body |
GB2090599B (en) * | 1981-01-05 | 1984-06-13 | Novo Industri As | Stabilized plasmin compositions and method for preparation thereof |
DE3751907T2 (en) * | 1986-05-15 | 1997-04-03 | Univ Emory | Injectable drug to protect against tissue damage from ischemia |
JP2507339B2 (en) | 1986-08-11 | 1996-06-12 | 三井東圧化学株式会社 | Purification method of crude tPA |
AT390801B (en) | 1988-07-28 | 1990-07-10 | Immuno Ag | METHOD FOR PRODUCING LYS PLASMINOGEN |
JPH0278633A (en) * | 1988-09-15 | 1990-03-19 | Green Cross Corp:The | Inactivation of virus |
US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
RO103682B1 (en) † | 1989-01-20 | 1992-03-26 | Institutul Cantacuzino | Isolation method of human ceruloplasmin |
US5237050A (en) * | 1989-03-29 | 1993-08-17 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
EP0399321B1 (en) * | 1989-05-24 | 1993-06-23 | Miles Inc. | Gel filtration of heat treated factor viii |
US5017292A (en) * | 1990-05-10 | 1991-05-21 | Millipore Corporation | Membrane, process and system for isolating virus from solution |
IT1260468B (en) * | 1992-01-29 | 1996-04-09 | METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL | |
JP2861655B2 (en) * | 1992-07-08 | 1999-02-24 | 吉富製薬株式会社 | Liquid preparation containing human urinary trypsin inhibitor and method for producing the same |
JPH0739375A (en) * | 1993-07-29 | 1995-02-10 | Green Cross Corp:The | Purification of plasminogen |
JP3761925B2 (en) * | 1995-06-26 | 2006-03-29 | 第一化学薬品株式会社 | Stable plasmin solution |
JPH099998A (en) * | 1995-06-26 | 1997-01-14 | Dai Ichi Pure Chem Co Ltd | Stable plasmin solution |
JP3622286B2 (en) * | 1995-09-01 | 2005-02-23 | 日東紡績株式会社 | α2-plasmin inhibitor measurement method and reagent |
WO1997015572A1 (en) † | 1995-10-25 | 1997-05-01 | Janssen Pharmaceutica N.V. | Lubeluzole n-oxide |
EP0860444A1 (en) | 1997-02-24 | 1998-08-26 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) | Method for removing viruses from a protein solution |
CN1167823A (en) * | 1997-03-25 | 1997-12-17 | 黄成已 | Method for producing health wine contg. compound active biological enzyme |
US6694764B1 (en) | 2003-03-21 | 2004-02-24 | Delphi Technologies, Inc. | Air conditioning system with electric compressor |
-
1999
- 1999-11-13 US US09/438,331 patent/US6355243B1/en not_active Expired - Lifetime
-
2000
- 2000-11-13 WO PCT/US2000/042143 patent/WO2001036611A1/en active Application Filing
- 2000-11-13 EP EP00990910A patent/EP1232252B1/en not_active Expired - Lifetime
- 2000-11-13 CA CA2389345A patent/CA2389345C/en not_active Expired - Lifetime
- 2000-11-13 AU AU30724/01A patent/AU784534B2/en not_active Expired
- 2000-11-13 PT PT00991956T patent/PT1232254E/en unknown
- 2000-11-13 AU AU16025/01A patent/AU784598B2/en not_active Expired
- 2000-11-13 DE DE60040345T patent/DE60040345D1/en not_active Expired - Lifetime
- 2000-11-13 EP EP00991956A patent/EP1232254B1/en not_active Expired - Lifetime
- 2000-11-13 JP JP2001538488A patent/JP4988115B2/en not_active Expired - Lifetime
- 2000-11-13 ES ES00990910T patent/ES2326616T3/en not_active Expired - Lifetime
- 2000-11-13 PT PT00990910T patent/PT1232252E/en unknown
- 2000-11-13 DE DE60036017.2T patent/DE60036017T3/en not_active Expired - Lifetime
- 2000-11-13 WO PCT/US2000/031090 patent/WO2001036608A1/en active Application Filing
- 2000-11-13 JP JP2001538490A patent/JP5025868B2/en not_active Expired - Lifetime
- 2000-11-13 AU AU36436/01A patent/AU784800B2/en not_active Expired
- 2000-11-13 JP JP2001538487A patent/JP2003514789A/en not_active Withdrawn
- 2000-11-13 WO PCT/US2000/031115 patent/WO2001036609A1/en active IP Right Grant
- 2000-11-13 DK DK00990910T patent/DK1232252T3/en active
- 2000-11-13 ES ES00991956T patent/ES2313912T3/en not_active Expired - Lifetime
- 2000-11-13 EP EP00978572.6A patent/EP1232251B2/en not_active Expired - Lifetime
- 2000-11-13 CA CA2389487A patent/CA2389487C/en not_active Expired - Lifetime
- 2000-11-13 DK DK00991956T patent/DK1232254T3/en active
- 2000-11-13 ES ES00978572.6T patent/ES2290058T5/en not_active Expired - Lifetime
- 2000-11-13 DE DE60042214T patent/DE60042214D1/de not_active Expired - Lifetime
- 2000-11-13 CA CA2389337A patent/CA2389337C/en not_active Expired - Lifetime
- 2000-11-13 EP EP08010118A patent/EP1956082A1/en not_active Withdrawn
- 2000-11-13 AT AT00990910T patent/ATE431401T1/en active
- 2000-11-13 AT AT00991956T patent/ATE409222T1/en active
-
2002
- 2002-05-10 US US10/143,112 patent/US20030012778A1/en not_active Abandoned
- 2002-05-10 US US10/143,156 patent/US20020192794A1/en not_active Abandoned
-
2008
- 2008-08-25 US US12/197,617 patent/US7871608B2/en not_active Expired - Fee Related
- 2008-12-10 CY CY20081101434T patent/CY1108639T1/en unknown
-
2009
- 2009-07-07 CY CY20091100721T patent/CY1110516T1/en unknown
-
2013
- 2013-02-07 US US13/761,684 patent/US9879246B2/en not_active Expired - Fee Related
- 2013-02-07 US US13/761,676 patent/US20130164815A1/en not_active Abandoned
- 2013-07-11 CY CY2013030C patent/CY2013030I2/en unknown
- 2013-07-12 NL NL300603C patent/NL300603I2/nl unknown
- 2013-07-12 FR FR13C0041C patent/FR13C0041I2/en active Active
- 2013-07-17 LU LU92255C patent/LU92255I2/en unknown
- 2013-07-18 BE BE2013C050C patent/BE2013C050I2/fr unknown
Patent Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3950513A (en) * | 1965-12-03 | 1976-04-13 | Novo Terapeutisk Laboratorium A/S | Process of stabilizing therapeutically useful plasmin solutions |
US3434929A (en) * | 1966-07-12 | 1969-03-25 | American Cyanamid Co | Process for purifying plasmin |
US3950223A (en) * | 1972-12-07 | 1976-04-13 | Ajinomoto Co., Inc. | Stabilizing and enhancing urokinase activity |
US4177262A (en) * | 1974-12-17 | 1979-12-04 | Choay S.A. | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots |
US4082612A (en) * | 1976-09-24 | 1978-04-04 | Michael Reese Research Foundation | Plasminogen activator complex |
US4361652A (en) * | 1980-01-25 | 1982-11-30 | The Green Cross Corporation | Method for stabilizing plasminogen |
US4361653A (en) * | 1980-07-03 | 1982-11-30 | The Green Cross Corporation | Plasminogen preparations |
US4446316A (en) * | 1980-12-31 | 1984-05-01 | Vsesojuzny Kardiologichesky Nauchny Tsentr | Dextran derivative of fibrinolysin |
US4462980A (en) * | 1981-01-05 | 1984-07-31 | Novo Industri A/S | Stabilized plasmin compositions and method for preparation thereof |
US4442213A (en) * | 1981-05-14 | 1984-04-10 | Behringwerke Aktiengesellschaft | Process for the preparation of plasminogen and plasminogen thus prepared |
US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
US4663146A (en) * | 1983-07-29 | 1987-05-05 | Codon Genetic Engineering Laboratories | Methods and compositions for the diagnosis of bloodclots using plasminogen activator |
US4908204A (en) * | 1983-12-24 | 1990-03-13 | Beecham Group P.L.C. | Reversibly blocked plasmin, t-PA hybrid fibrinolytic enzymes and pharmaceutical compositions and anti-thrombotic use thereof |
US5112609A (en) * | 1985-05-28 | 1992-05-12 | Burroughs Wellcome Co. | Acidic formulations of t-PA |
US5068106A (en) * | 1987-06-05 | 1991-11-26 | Behringwerke Aktiengesellschaft | t-PA solution of high concentration and use of the solution in human and veterinary medicine |
US4774087A (en) * | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
US5024829A (en) * | 1988-11-21 | 1991-06-18 | Centocor, Inc. | Method of imaging coronary thrombi |
US5328996A (en) * | 1989-03-29 | 1994-07-12 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
US5165912A (en) * | 1989-08-18 | 1992-11-24 | Novo Nordisk A/S | Method for the detection of fibrinolytic activity |
US5304383A (en) * | 1990-10-11 | 1994-04-19 | Immuno Aktiengesellschaft | Pharmaceutical preparation based on Lys-plasminogen |
US5290692A (en) * | 1991-03-26 | 1994-03-01 | Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry | Bioadaptable porous crystalline glass containing an immobilized fibrinolytic enzyme for dissolving blood clots |
US5288489A (en) * | 1991-08-28 | 1994-02-22 | Orion Therapeutic Systems, Inc. | Fibrinolysis and fibrinogenolysis treatment |
US5407673A (en) * | 1991-08-28 | 1995-04-18 | Orion Therapeutic Systems, Inc. | Fibrinolysis and fibrinogenolysis treatment |
US5587291A (en) * | 1992-04-14 | 1996-12-24 | Berbi Gesellschaft M.B.H. | Method for the determination of plasmin α2 -antiplasmin complexes and the use of this method as a mean of determining changes in the fibrinolytic system |
US5472692A (en) * | 1993-07-02 | 1995-12-05 | New England Deaconess Hospital Corporation | Pro-urokinase mutants |
US5407678A (en) * | 1993-09-01 | 1995-04-18 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Petroleum jelly cream |
US5728674A (en) * | 1993-11-05 | 1998-03-17 | Zymogenetics, Inc. | Inhibition of blood coagulation by human-kunitz-type inhibitors |
US5776452A (en) * | 1994-03-30 | 1998-07-07 | Immuno Aktiengesellschaft | Thrombosis agent |
US5928218A (en) * | 1994-12-16 | 1999-07-27 | Gelbfish; Gary A. | Medical material removal method and associated instrumentation |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US5879923A (en) * | 1995-06-26 | 1999-03-09 | Daiichi Pure Chemicals Co., Ltd. | Stable plasmin solution |
US6207066B1 (en) * | 1996-07-23 | 2001-03-27 | Nuvue Technologies, L.L.C. | Method for purification of a blood component |
US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
US6479253B1 (en) * | 1996-11-07 | 2002-11-12 | Heska Corporation | Serine protease inhibitor nucleic acid molecules and uses thereof |
US6969515B2 (en) * | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US20010004256A1 (en) * | 1999-12-21 | 2001-06-21 | Satoshi Iwata | Display system, display control method and computer readable medium storing display control program code |
US7181417B1 (en) * | 2000-01-21 | 2007-02-20 | Microstrategy, Inc. | System and method for revenue generation in an automatic, real-time delivery of personalized informational and transactional data |
US20020091737A1 (en) * | 2000-11-01 | 2002-07-11 | Markel Steven O. | System and method for rules based media enhancement |
US20030093423A1 (en) * | 2001-05-07 | 2003-05-15 | Larason John Todd | Determining a rating for a collection of documents |
US7027051B2 (en) * | 2001-06-29 | 2006-04-11 | International Business Machines Corporation | Graphical user interface for visualization of sampled data compared to entitled or reference levels |
US7015911B2 (en) * | 2002-03-29 | 2006-03-21 | Sas Institute Inc. | Computer-implemented system and method for report generation |
US20040030795A1 (en) * | 2002-08-07 | 2004-02-12 | International Business Machines Corporation | System, method and program product for inserting targeted content into a portlet content stream |
US20040268228A1 (en) * | 2003-06-19 | 2004-12-30 | Microsoft Corporation | Framework for creating modular web applications |
US6963826B2 (en) * | 2003-09-22 | 2005-11-08 | C3I, Inc. | Performance optimizer system and method |
US20050108271A1 (en) * | 2003-11-13 | 2005-05-19 | St. Jude Children's Research Hospital, Inc. | System and method for defining and collecting data in an information management system having a shared database |
US20070038934A1 (en) * | 2005-08-12 | 2007-02-15 | Barry Fellman | Service for generation of customizable display widgets |
US7496852B2 (en) * | 2006-05-16 | 2009-02-24 | International Business Machines Corporation | Graphically manipulating a database |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116676A1 (en) * | 2002-09-30 | 2004-06-17 | Hotta Joann | Methods for removal of contaminants from blood product solutions |
US20080050356A1 (en) * | 2002-12-06 | 2008-02-28 | Thromb-X Nv | Pharmacological vitreolysis |
US8460655B2 (en) | 2002-12-06 | 2013-06-11 | Thrombogenics Nv | Pharmacological vitreolysis |
US20080095753A1 (en) * | 2002-12-06 | 2008-04-24 | Thromb-X Nv | Pharmacological vitreolysis |
US20090074739A1 (en) * | 2002-12-06 | 2009-03-19 | Thromb-X Nv | Pharmacological vitreolysis |
US8834869B2 (en) | 2002-12-06 | 2014-09-16 | Thrombogenics Nv | Pharmacological vitreolysis |
US8747842B2 (en) | 2002-12-06 | 2014-06-10 | Thrombogenics Nv | Pharmacological vitreolysis |
US20050118158A1 (en) * | 2002-12-06 | 2005-06-02 | Thromb-X Nv | Pharmacological vitreolysis |
US8383105B2 (en) | 2002-12-06 | 2013-02-26 | Thrombogenics Nv | Pharmacological vitreolysis |
US20110171190A1 (en) * | 2002-12-06 | 2011-07-14 | Thrombogenics Nv | Pharmacological vitreolysis |
US7914783B2 (en) | 2002-12-06 | 2011-03-29 | Thrombogenics Nv | Pharmacological vitreolysis |
US9186394B2 (en) | 2002-12-06 | 2015-11-17 | Thrombogenics Nv | Pharmacological vitreolysis |
US7547435B2 (en) | 2002-12-06 | 2009-06-16 | Thrombogenics Nv | Pharmacological vitreolysis |
US7803368B2 (en) | 2002-12-06 | 2010-09-28 | Thrombogenics Nv | Pharmacological vitreolysis |
US9770494B2 (en) | 2002-12-06 | 2017-09-26 | Thrombogenics Nv | Pharmacological vitreolysis |
AU2006245575B2 (en) * | 2005-05-09 | 2010-01-28 | Prometic Biotherapeutics Inc. | Affinity adsorbents for plasminogen |
WO2006120423A1 (en) * | 2005-05-09 | 2006-11-16 | Prometic Biosciences Ltd. | Affinity adsorbents for plasminogen |
US7998960B2 (en) | 2005-05-09 | 2011-08-16 | Prometic Biosciences Ltd. | Affinity adsorbents for plasminogen |
US20080293925A1 (en) * | 2005-05-09 | 2008-11-27 | Jason Richard Betley | Affinity Adsorbents for Plasminogen |
US20080008698A1 (en) * | 2005-05-11 | 2008-01-10 | Bartels Stephen P | Non-Surgical Method for Preventing or Reducing the Rate of the Progression of Non-Proliferative Diabetic Retinopathy and the Treatment of Other Ocular Conditions |
US20070128182A1 (en) * | 2005-05-11 | 2007-06-07 | Bartels Stephen P | Non-Surgical Method for Preventing or Reducing the Rate of the Progression of Non-Proliferative Diabetic Retinopathy and the Treatment of Other Ocular Conditions |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
US20070134230A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes |
US20070134231A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes and compositions thereof |
US20110201077A1 (en) * | 2008-06-04 | 2011-08-18 | Talecris Biotherapeutics ,Inc. | Composition, method, and kit for preparing plasmin |
WO2009149199A3 (en) * | 2008-06-04 | 2010-04-01 | Talecris Biotherapeutics, Inc. | Composition, method and kit for preparing plasmin |
RU2497948C2 (en) * | 2008-06-04 | 2013-11-10 | Тэйлкрис Байотерапьютикс, Инк. | Composition, method and set for production of plasmin |
US8617863B2 (en) | 2008-06-04 | 2013-12-31 | Grifols Therapeutics Inc. | Composition, method, and kit for preparing plasmin |
AU2009256168B2 (en) * | 2008-06-04 | 2014-06-05 | Grifols Therapeutics Inc. | Composition, method and kit for preparing plasmin |
US9206410B2 (en) | 2009-03-03 | 2015-12-08 | Grifols Therapeutics Inc. | Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1232254B1 (en) | Process for the production of a reversibly inactive acidified plasmin composition | |
US8268782B2 (en) | Composition and method for preparing plasminogen | |
US5112609A (en) | Acidic formulations of t-PA | |
JPH0378375B2 (en) | ||
JP2007068497A (en) | Method for purifying plasmin | |
US20070134230A1 (en) | Method for prolonging activity of autodegradable enzymes | |
US20050143283A1 (en) | Activated protein c formulations | |
JPH05170665A (en) | Pharmaceutical preparation containing thrombolytically active substance | |
JPS6338327B2 (en) | ||
JPH07291999A (en) | Platelet stabilization factor ix-fragment, its production, and chemical containing it | |
RU2257224C1 (en) | Method for preparing human plasmin concentrate and product for its using in medicine | |
Novokhatny et al. | Acid‐Stabilized Plasmin as a Novel Direct‐Acting Thrombolytic | |
ES2371208T3 (en) | PROCEDURE FOR ACTIVATING PRETROMBIN 1. | |
JPH08268910A (en) | Drug for hypodermic administration of protein c | |
JPH03130231A (en) | Pharmaceutical preparation | |
JP2000247904A (en) | Cerebral blood vessel twitching treatment agent and hematoma remover |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER HEALTH CARE, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DADD, CHRISTOPHER A.;STENLAND, CHRISTOPHER J.;KENT, JONATHAN D.;AND OTHERS;REEL/FRAME:013711/0631;SIGNING DATES FROM 20030512 TO 20030522 |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:013775/0327 Effective date: 20030623 |
|
AS | Assignment |
Owner name: BAYER HEALTH CARE LLC, NEW YORK Free format text: TO CORRECT ASSIGNMENT REGARDING SPELLING OF ASSIGNOR, TANETTE B. VILLINES NAME REEL/FRAME NO. 013711/0631; RECORDATION DATE 06/05/2003;ASSIGNORS:DADD, CHRISTOPHER A.;STENLAND, CHRISTOPHER J.;KENT, JONATHAN D.;AND OTHERS;REEL/FRAME:013873/0222 Effective date: 20030605 |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.;REEL/FRAME:016087/0461 Effective date: 20050331 |
|
AS | Assignment |
Owner name: TALECRIS BIOTHERAPEUTICS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER HEALTHCARE LLC;REEL/FRAME:016757/0664 Effective date: 20050331 |
|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS THE ADMINI Free format text: PATENT SECURITY AGREEMENT SECOND LIEN;ASSIGNORS:TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.;TALECRIS BIOTHERAPEUTICS, INC.;PRECISION PHARMA SERVICES, INC.;AND OTHERS;REEL/FRAME:019047/0276 Effective date: 20061206 Owner name: WACHOVIA BANK, NATIONAL ASSOCIATION, AS ADMINISTRA Free format text: SECURITY AGREEMENT;ASSIGNORS:TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.;TALECRIS BIOTHERAPEUTICS, INC.;PRECISION PHARMA SERVICES, INC.;AND OTHERS;REEL/FRAME:019047/0296 Effective date: 20061206 Owner name: WELLS FARGO FOOTHILL, INC., AS COLLATERAL AGENT, C Free format text: SECURITY AGREEMENT;ASSIGNORS:TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.;TALECRIS BIOTHERAPEUTICS, INC.;PRECISION PHARMA SERVICES, INC.;AND OTHERS;REEL/FRAME:019047/0296 Effective date: 20061206 Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS THE ADMINI Free format text: PATENT SECURITY AGREEMENT FIRST LIEN;ASSIGNORS:TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.;TALECRIS BIOTHERAPEUTICS, INC.;PRECISION PHARMA SERVICES, INC.;AND OTHERS;REEL/FRAME:019047/0317 Effective date: 20061206 |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNORS:GRIFOLS, S.A.;GRIFOLS INC.;TALECRIS BIOTHERAPEUTICS, INC.;REEL/FRAME:026390/0193 Effective date: 20110601 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |
|
AS | Assignment |
Owner name: GRIFOLS, S.A., SPAIN Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:041494/0017 Effective date: 20140227 Owner name: GRIFOLS INC., CALIFORNIA Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:041494/0017 Effective date: 20140227 Owner name: TALECRIS BIOTHERAPEUTICS, INC., CALIFORNIA Free format text: RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH;REEL/FRAME:041494/0017 Effective date: 20140227 |